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                                                        ABSTRACT 
BACKGROUND:  
          Oral squamous cell carcinoma(OSCC) is the sixth most common human cancer, with an 
increasing incidence in younger people causing a high morbidity &mortality rate in older 
persons. The mainstay of treatment for OSCC is usually surgery followed by radiotherapy. One 
of the important complication of Radiotherapy is its potential to damage the major salivary 
glands. It causes morphological alterations in the glands and also affects the composition of 
saliva. 
AIM: 
           To analyse ultrasonographic changes of parotid and submandibular salivary glands and 
Biochemical analysis of whole saliva in oral cancer patients before and after radiotherapy 
OBJECTIVES: 
              Ultrasonographic analysis of parotid &submandibular salivary glands size , margins, 
echotexture, echogenicity,and vascularity(colour Doppler) before and six weeks after 
radiotherapy and Assessment of  salivary Na, K, Ca, pH, salivary amylase , salivary total protein 
in oral cancer patients before and six weeks after  radiotherapy. 
METHODS: 
                   A total of 30 oral cancer patients   were selected for this study. Among the 30 
patients 23 were males and 7 females. Age range of the patient was 30-70. All were planned for 
conventional radiation treatment. 
          Ultrasonographic evaluation of 60 parotids and 60 submandibular glands were done prior 
to radiotherapy and six weeks after completion of radiotherapy. Unstimulated Whole saliva was 
collected under resting conditions in a quiet room, between 8 am and noon, at least 1 hour after 
food intake in same patients on the day of ultrasound. 
RESULTS: 
       When comparing the post radiotherapy USG changes of salivary glands length, width, depth 
with preradiotherapy USG values, and the salivary salivary biochemical pre and post 
radiotherapy values, we found that the results were statistically significant. P value =0.000. 
CONCLUSION:          
     On ultrasonographic examination we observed decrease in size of salivary glands following 
radiotherapy. There was significant decrease in length, width and depth and changes in margin 
from regular to irregular, echotexture from homogenous to heterogenous and echogenicity from 
hyperechoic to hypoechoic. This changes salivary glands can be related to chronic inflammation 
which sets in the glands after exposure to radiation and which leads to subsequent fibrous 
changes in glands. In salivary evaluation pH is significantly reduced, Na, Ca, Total protein levels 
were significantly increased. Pottasium and salivary amylase levels were significantly reduced 
after radiotherapy. These changes can be related to parenchymal damage and acinar loss. 
KEY WORDS: 
        Oral cancer, Radiotherapy, Ultrasonography, Salivary glands 
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 INTRODUCTION 
        Oral cancer is a broad term that includes various malignant diagnoses that present in the 
oral tissues. Oral squamous cell carcinoma (OSCC) is the sixth most common human cancer, 
with an increasing incidence in younger people causing a high morbidity &mortality rate in 
older persons. Even though the management and prognosis may be different between types 
and stages of oral cancer, It always has a dramatic impact on the patient’s life. Although the 
older literature combines oral cancer and oropharyngeal cancer, now a days it is recognized 
that both cancers should be evaluated individually for the ease of assessment of epidemiology, 
pathogenesis and treatment outcomes. The oral cavity includes the lips, the labial and buccal 
mucosa, the anterior two-thirds of the tongue, the retromolar pad, the floor of the mouth, the 
gingival, the hard palate. Oro pharynx includes the palatine and lingual tonsils, the posterior 
one-third of the tongue, the soft palate, and posterior pharyngeal wall.
1 
              In South Asia, oral cancer accounts for about up to 40% of all cancers. In India, the 
incidence of oral cancer is about 3–7 times more common as compared with the resource-rich 
countries. Oral cancer is the 3rd most common cancer in India after cervical and breast cancer 
among women. The increased prevalence of the oral cancer in the subcontinent of India seems 
to be due to smoking, use of smokeless tobacco, alcohol, spicy food and lack of fruit or fiber 
intake, and neglected oral health and hygiene.  
         In the West, the cancers in the floor of mouth and tongue are common whereas in the 
Indian subcontinent the cancers of gingivobuccal sulcus, tongue, buccal mucosa are common 
due to placement of tobacco quid under the tongue, under the buccal mucosa and under the lip.         
Tobacco and alcohol are strong synergistic effects or oral cancer. There are strong synergistic 
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effects on oral cancer risk when a person has both the habit of smoking & drinking, tobacco 
usage including smokeless tobacco and excessive intake of alcohol which is estimated to 
account for about 90% of oral cancers.
2 
                        The mainstay of treatment for OSCC is usually surgery
3
 followed by 
radiotherapy [external beam radiotherapy (EBRT) and/or brachytherapy], or various 
combinations of these modalities with or without the use of systemic therapy like chemother-
apy and/or target agents. The basis of treatment selection depends on considerations of disease 
control, anticipated functional and cosmetic outcomes, and availability of resources and 
expertise. OSCCs are considered radiosensitive and early lesions are highly curable mainly T1 
and T2 lesions. 
 One of the important complication of Radiotherapy is its potential to damage the major 
salivary glands. There are three pairs of major salivary glands in human body namely parotid 
glands, submandibular glands and sublingual glands. Moreover, numerous minor salivary 
glands are also found in the oral cavity 
        Parotid glands contributes the majority of stimulated saliva and submandibular glands 
contribute approximately 2/3rds of un stimulated saliva volume.
4 
Saliva is the product of 
multiple salivary glands both major and minor. Salivary gland plays an important role in oral 
health by aiding in digestion of food, protection of oral mucosa, it also facilitates 
remineraliation of dental hard tissues and moisturizing palate for articulation. Each gland has a 
unique combination of mucous and serous acinar cells which are responsible for synthesizing 
protein componants of saliva and transporting water and electrolytes.  
3 
 
The complications  of  Radiotherapy is due to effects on vascular, connective and parenchymal 
tissues.
 
 The radiation uptake by salivary glands during radiotherapy for oral cancers alters the 
parenchymal structure and vascularity resulting viscosity and volume changes of secreted 
saliva.
5
 Due to the functionl and structural alterations of the salivary glands, biochemical 
alterations of saliva also occurs. Despite their slow turnover rate, the serous cells are highly 
radiosensitive. In submandibular glands, the selective destruction of serous acini was 
particularly apparent within the normal mix of cells. Although acinar cells can recover and 
repopulate, the typical therapeutic radiation doses eventually damage the ducts, ductal stem 
cells, and the mucinous and supporting stromal and vascular cells. This damage often result in 
xerostomia and fibrosis. A radiation dose as low as 20 Gy can cause permanent cessation of 
salivary flow if given as a single dose. At doses above 52Gy, salivary dysfunction becomes 
severe. Treatment of oral carcinoma traditionally involves the administration of a dose of 
60Gy to 70Gy and this can lead to a rapid decrease in flow during the first week of radiation, 
with an eventual reduction of 95% in the region. By 5 weeks of radiation, the flow virtually 
ceases and rarely recovers completely. Both resting and stimulated salivary flow are inhibited. 
          Various imaging modalities were used to evaluate the radiation induced salivary gland 
changes which includes CT scan,MRI and sonography. Ultrasonography is a simple and safe 
technique for the evaluation of salivary gland changes caused by radiotherapy.
6 
            Ultrasonographic(USG) imaging is considered as a “real-time” imaging, which 
generate electrical impulses that are converted into sound waves of high frequency by a 
transducer and then transmitted into the tissues to be examined. It is then reflected as echoes 
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and reconverted into electrical energy, amplified, processed, and displayed on the monitor.
7
 
USG is particularly suitable for imaging superficial structures of the oral mucosa and provides 
both quantitative and qualitative assessment, the nature and dimension of lesion or structure.
8 
              Based on this the study is planned to evaluate the changes in Parotid and 
Submandibular salivary glands in patients with oral cancer undergoing radiotherapy treatment 
using Ultrasonography and biochemical analysis(Na, K, Ca, PH, amylase, Total protein) of  
their saliva at the same time. 
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AIM AND OBJECTIVES 
AIM: 
      To analyse ultrasonographic changes of parotid and submandibular salivary glands and 
Biochemical analysis of whole saliva in oral cancer patients before and after radiotherapy.  
OBJECTIVES: 
1. Ultrasonographic analysis of parotid &submandibular salivary glands size ,margins, 
Echotexture, Echogenicity,and vascularity (colour Doppler)  before radiotherapy.  
2.  Assessment of salivary Na, K, Ca, pH, salivary amylase, salivary total protein in oral 
cancer patients before radiotherapy. 
3. Ultrasonographic analysis of parotid & submandibular salivary glands size, margins, 
Echotexture, Echogenicity, and vascularity(colour Doppler) six weeks after completion 
of radiotherapy. 
4.  Assessment of salivary Na, K, Ca, pH, salivary amylase, salivary total protein in oral 
cancer patients six weeks after completion of radiotherapy. 
5. To compare the pre radiotherapy Ultrasonographic analysis of parotid and 
submandibular gland with post radiotherapy ultrasonographic changes.  
6. To compare the pre radiotherapy biochemical values of saliva with post radiotherapy 
values. 
7. To find association between TNM staging of tumour with pre and post radiotherapy 
Ultrasonographic salivary gland changes. 
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 REVIEW OF LITERATURE 
                 Our oldest description of cancer (although the word cancer was not used) was 
discovered in Egypt and dates back to about 3000 BC. It’s called the Edwin Smith Papyrus 
and is a copy of part of an ancient Egyptian textbook on trauma surgery.  
        The origin of the word cancer is credited to the Greek physician Hippocrates (460-370 
BC), who is considered the “Father of Medicine.” Hippocrates used the terms carcinos and 
carcinoma to describe non-ulcer forming and ulcer-forming tumors. In Greek, these words 
refer to a crab, most likely applied to the disease because the finger-like spreading projections 
from a cancer called to mind the shape of a crab.
9 
Head and neck malignancies comprise 3–5% of all malignancies in worldwide.2In 
epidemiology studies the term ‘oral cancer’ is sometimes employed to connote both oral 
cavity cancer and oropharyngeal cancer. However, these are different clinical entities and in 
contemporary practice often have different etiologies and are frequently managed differently 
according to American Joint Committee on Cancer (AJCC) and the Union for International 
Cancer Control (UICC) in the tumor-node-metastasis (TNM) staging classification squamous 
cell carcinomas of the oral cavity (OSCC) originating from the mucosal lip, anterior two-thirds 
of the tongue (oral tongue), buccal mucosa, floor of mouth, hard palate, lower and upper 
alveolus and gingiva, and the retromolar trigone.
3 
             The mainstay of treatment for OSCC is usually surgery.
10
 EBRT with or without 
chemotherapy is generally employed in 3 situations: a) adjuvant to primary surgery to enhance 
loco-regional control (LRC) for cases with unfavorable pathological features, b) primary 
treatment for cases unable to tolerate or unsuited for surgery, and c) salvage treatment in the 
persistent or recurrent disease setting. Brachytherapy may be employed as a sole modality for 
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early disease with a well-defined primary tumor, or as an adjuvant to surgery for cases with 
close or positive resection margins. Alternatively it may be used as a “boost” technique to the 
primary tumor in addition to EBRT.
1 
Evolution of radiotherapy 
Radiation therapy is shaped by the efforts of many scientists in medicine, biology, 
physics as well as people in allied professions such as administration, computer science and 
architecture.  
The radiotherapy era was divided into six periods, each 20 years long. 
1. Discovery phase:                       :1898-1910 
2. Empirical radiotherapy phase            :1910-1930 
3. Scientific radiotherapy phase            :1930-1950 
4. Transition to megavoltage phase           :1950-1970 
5. Modernization phase (buildings & machines).         :1970-1990 
6. High technology phase         : 1990- present 
Rothwell states that most orofacial complications are dose dependent and that severe side 
effect occurs when doses <45 Gy administered be the bilaterally to the mouth, jaws, and 
salivary gland.
11
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PRINCIPLES OF RADIOTHERAPY 
 
Effects of radiation at cellular level 
The effectiveness of ionizing radiation on a biologic system depends not only on the amount 
of radiation deposited but also on the state of the biologic system. One of the first laws of 
radiation biology, postulated by Bergonie and Tribondeau, stated in essence that the 
radiosensitivity of a tissue is dependent on the number of undifferentiated cells in the tissue, 
the degree of mitotic activity of the tissue, and the length of time that cells of the tissue remain 
in active proliferation.
3
  
  The primary target of ionizing radiation is the DNA molecule, and the human cell is 
most radiosensitive during mitosis. Current research tends to indicate that all cells are equally 
radiosensitive; however, the manifestation of the radiation injury occurs at different time 
frames (i.e., acute versus late effects).  
Because tissue cells are composed primarily of water, most of the ionization occurs 
with water molecules. These events are called indirect effects and result in the formation of 
free radicals such as OH, H
+
 and HO
2-
. These highly reactive free radicals may recombine 
with no resultant biologic effect, or they may combine with other atoms and molecules to 
produce biochemical changes that may be deleterious to the cell. The possibility also exists 
that the radiation may interact with an organic molecule or atom, which may result in the 
inactivation of the cell; this reaction is called the direct effect. Because ionizing radiation is 
nonspecific (i.e., it interacts with normal cells as readily as with tumour cells), cellular damage 
will occur in both normal and abnormal tissue. The deleterious effects, however, are greater in 
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the tumour cells because a greater percentage of these cells are undergoing mitosis and tumour 
cells also tend to be more poorly differentiated. In addition, normal cells have a greater 
capability for repairing sublethal damage than do tumour cells. Thus greater cell damage 
occurs to tumour cells than to normal cells for any given increment of dose. 
In terms of cellular lethality from ionizing radiation, DNA is generally considered to 
be a principal intracellular target. Although both single-strand breaks and double-strand 
breaks (DSBs) are observed, it is the double-strand breaks that are thought to represent the 
lethal event.  
 VARIOUS MODES OF RADIOTHERAPY 
Three types of radiations are used:  gamma, beta and X-rays. The radiation is 
concentrated onto the site of the tumour to damage the chromosomes in the rapidly-
growing cancer cells. 
Types of radiation therapy 
1. External (transcutaneous): Irradiation from sources at a distance from the body (X-ray, 
teletherapy with radium – 226, cobalt – 60 or cesium – 137). 
2. Local irradiation (brachytherapy): Irradiation from source in direct contact with the 
tumor: 
a) Surface irradiation with applicators loaded with radioactive material (moulds for 
treatment for certain oral tumors like carcinoma of hard palate and skin tumor). 
b) Intra cavitary irradiation with radio-active material (most commonly radium 226, 
cobalt-60 and cesium–137) in removable applicators which are inserted into body 
cavities, such as uterus, vagina nasopharynx or maxillary sinus. 
10 
 
c) Interstitial irradiation by removable needles containing radium – 226, cobalt – 
60,cesium – 137; by non-removable “seeds”  of radioactive gold – 198 or radon ; by 
small radioactive    iridium sources in nylon suture ;or by radioactive tantalum – 182 
wire. The radioisotope is implanted into the tumor, e.g. – carcinoma of tongue and 
buccal mucosa. 
d) Direct Roentgen therapy to epithelial lesions by means of cones (i.e. – transvaginal, 
intraoral). 
3. Intraoral or systematic irradiation: Eradiation by radioactive sources (i.e. - 32 p, 131 I) 
administered intravenously or parentally. Radioactive Iodine is used to treat thyroid cancer, 
and phosphorous – 32 is used for the treatment of polycythemia vera. Other methods like 
contact therapy, intraoperative, stereotactic hyperthermia are also  practiced.  
EXTERNAL BEAM TREATMENT 
A beam of ionising radiation is aimed at the cancerous growth in this treatment. The 
source of the beam is moved around. In this way, the beam is always focused on the tumour, 
but doesn't take the same route through healthy tissue. The tumour gets a high dose, while the 
surrounding healthy tissue gets a lower dose. External radiotherapy uses X-rays and 
sometimes gamma rays. X-rays or gamma rays, which are both forms of electromagnetic 
radiation.  Although they are produced in different ways, both use photons.  
Low and medium energy X-rays are particularly suitable for treating cancers on the 
outside of the body. To reach internal tumors requires very high energy radiation is required.  
This can be produced by super high voltage machines but sometimes, a radioactive source 
such as cobalt-60 or iridium-137 is used. When they decay, these radioactive sources produce 
high energy X-rays and gamma rays. These radiations are more penetrating and are therefore 
11 
 
more suitable for internal tumors. 
Gamma rays are produced when isotopes of certain elements release radiation energy 
when they break down. Each element breaks down at a specific rate and each gives off a 
different amount of energy, which affects how deeply it can penetrate into the body. Gamma 
rays produced by the breakdown of cobalt 60 are used in the treatment called the "gamma 
knife," The patient does not come into contact with any radioactive sources and does not 
become radioactive as a result of the treatment.  
Cobalt machines were the mainstay of radiation oncology departments in the 1960s. 
These units, sometimes called "teletherapy units", consisted of a large machine with cobalt 60 
housed in the head of the treatment unit. The unit although bulky, is diverse in its treatment 
scope, because patients can be treated in a rotational or fixed beam arrangement.  
INTERSTITIAL AND INTRACAVITARY TREATMENT 
Implant therapy (brachytherapy) is a method of radiation treatment using sealed 
radioactive sources placed at a short distances from the patient's tumor. These radioactive 
sources can be best described as interstitial or intracavitary. The interstitial method is the 
placement of a sealed radioactive source directly into the tumor, such as tongue. The 
intracavitary method is the placement of sealed radioactive source in a body cavity close to the 
tumor, such as the cervix.  
These types of radiotherapy usually use a source of beta radiation like technetium-99. 
Beta radiation is short range so its effects are much localized. This means that a higher dose 
can be given with less damage to surrounding tissues. In both the instances, these radioactive 
sources can be permanent or removable. Sources come in different forms (eg. needles, tubes & 
seeds). Radioactive substitutes also vary and include cesium, strontium 89, phosphorous, 
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phosphate, or cobalt, gold, tantalum & indium.  
Other methods of treatment 
Contact therapy 
It   is the placement of radioactive sources directly on the tumor. In this therapy the 
source is usually embedded in a mold and left on and the tumor for a specified period.  
INTRAOPERATIVE RADIATION THERAPY (IORT) & TOTAL BODY 
IRRADIATION (TBI) 
These are two newer methods of treatment. IORT delivers the radiation dosage directly 
to the tumor during surgery. This technique is used in tumors that are deeply situated in the 
body where surrounding radiosensitive organs can be moved out of the treatment area. 
Therefore a larger single dose can be delivered directly to the tumor with the aim of 
destroying the tumor & any residual disease. It is a costly time consuming procedure because 
of the necessity of combining the operating room's sterile- technique situation with the high 
energy equipment in a shielded room needed for radiation protection, This technique is used in 
selected cases.  In contrast, TBI focuses on irradiation of the entire body rather than a specific 
site. This technique is also used for only specific diseases. Patients preparing for bone marrow 
transplant are probably the most common candidates for TBI. Doses higher than those that 
cause death from bone marrow depletion can be given because bone marrow is replaced 
during the transplant. 
Hyperthermia 
This is another method of treatment.  The basic principle is that the heat sometimes 
causes regression in tumors. A special unit is needed to perform the heating procedure on the 
patient. Then the patient is treated with conventional radiation therapy.  
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Stereotactic radiosurgery 
This is a treatment technique that was introduced in the early 1950s. Stereotaxis (a 
method dealing with precise location in an area of the brain) is essential in this neurological 
procedure. The procedure does not involve actual surgery. The patient's head is placed in a 
special frame, which is attached to the patient' skull. The frame is used to aim high-dose 
radiation beams directly at the tumor inside the patient's head. The dose and area receiving the 
radiation are coordinated very precisely. Most nearby tissues are not damaged by this 
procedure. Stereotactic radiosurgery can be done in one of three ways. The most common 
technique uses a linear accelerator to administer high-energy photon radiation to the tumor. 
The gamma knife, the second most common technique, uses cobalt 60 to deliver radiation. 
The third technique uses heavy charged particle beams (such as protons and helium ions) to 
deliver stereotactic radiation to the tumor.  
Stereotactic radiosurgery is mostly used in the treatment of small benign and malignant 
brain tumors including meningioma, acoustic neuroma, and pituitary cancer. It can also be 
used to treat other conditions like Parkinson's disease and epilepsy. Stereotactic radiosurgery 
can be used to treat metastatic brain tumors (cancer that has spread to the brain from another 
part of the body) either alone or along with whole-brain radiation therapy. Whole brain 
radiation therapy is a form of external radiation therapy that treats the centre brain with 
radiation. 
Stereotactic radiotherapy uses essentially the same approach as stereotactic 
radiosurgery to deliver radiation to the target tissue. However, stereotactic radiotherapy uses 
multiple small tractions of radiation as opposed to one large dose. Giving multiple smaller 
doses may improve outcomes and minimize side effects. Stereotactic radiotherapy is used to 
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treat tumors in the brain as well as other parts of the body. Clinical trails are under way to 
study the effectiveness of stereotactic radiosurgery and stereotactic radiotherapy alone and in 
combination with other types of radiation therapy. 
 
THREE –DIMENSIONAL (3-D) CONFORMAL RADIATION THERAPY 
Traditionally, the planning of radiation treatments has been done in two dimensions 
(which and height). Three-dimensional (3-D) conformal radiation therapy uses computer 
technology to allow doctors to more precisely target a tumor with radiation beams (using 
width, height, and depth). Many radiation oncologists use this technique. A 3-D image of a 
tumor can be obtained using computed tomography (CT), magnetic resonance imaging (MRI), 
positron emission tomography (PET), or single photon emission computed tomography 
(SPECT). Using information from the image, special computer programs design radiation 
beams that “conform” to the shape of the tumor. Because the healthy tissue surrounding the 
tumor is largely spared by this technique; higher doses of radiation can be used to treat the 
cancer. Improved outcomes with 3-D conformal radiation therapy have been reported for 
nasopharyngeal, prostate, lung, liver, and brain cancers. 
INTENSITY-MODULATED RADIATION THERAPY (IMRT) 
IMRT is a new type of 3-D conformal radiation therapy that uses radiation beam 
(usually x-rays) of varying intensities to deliver different doses of radiation to small areas of 
tissue at the same time. The technology allows for the delivery of higher doses of radiation 
within the tumor and lower doses to nearby healthy tissue. Some techniques deliver a higher 
dose of radiation to the patient each day, potentially shortening the overall treatment time and 
improving the success of the treatment. IMRT may also lead to fewer side effects during 
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treatment.  
The radiation is delivered by a linear accelerator that is equipped with a multileaf 
collimator (a collimator helps to shape or sculpt the beams of radiation). The equipment can 
be rotated around the patient so that radiation beams can be sent from the best angles. The 
beams conform as closely as possible to the shape of the tumor. Because IMRT equipment is 
highly specialized, not every radiation oncology center uses IMRT.  
This new technology has been used to treat tumors in the brain, head and neck, 
nasopharynx, breast, liver, lung, prostate, and uterus. However, IMRT is not appropriate or 
necessary for every patient or tumor type. Long-term results following treatment with TMRT 
are becoming available.  
Low –LET and high-LET radiation linear energy transfer (LET) describes the rate at 
which a type of radiation deposits energy as it passes through tissue. Higher levels of 
deposited energy cause more cells to be killed by a given dose of radiation therapy. Different 
types of radiation have different levels of LET. For example, x-rays, gamma rays and 
electrons are known as low-LET radiation. Neutrons, heavy ions, and pions are classified as 
high-LET radiation. Most high-LET radiation is investigational treatment. The cost of the 
equipment and the amount of specialized training needed to perform high-LET radiation 
therapy restrict its use to only a few facilities in the United States. 
ANATOMY OF SALIVARY GLANDS 
There are three pairs of major salivary glands in human body namely parotid glands, 
submandibular glands and sublingual glands. Moreover, numerous minor salivary glands are 
also found in the oral cavity. 
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Parotid gland: 
Parotid gland is the largest salivary gland, which is located in the retromolar fossa. It is 
anterior to external auditory meatus, inferior to zygomatic arch, posterior and superior to angle 
of mandible and anteriorly overlaps with masseter muscle. It is composed of serous acinar 
cells, which produce serous saliva, mainly water in content. The imaginary phase formed by 
facial nerve divides the parotid gland into superficial and deep lobe.
12 
The main salivary duct 
of parotid gland is stensen’s duct which passes through buccinator muscle and enters the oral 
cavity through buccal mucosa at the upper second molar tooth level. Parotid gland mainly 
secretes saliva in stimulated conditions like chewing, and it secrets up to60% of saliva during 
mastication.
13 
Submandibular gland: 
Submandibular glands is the second largest salivary gland, which is located under the floor of 
the oral cavity, anterior and inferior to parotid gland, posterior and inferior to mylohyoid 
muscle and superior to digastrics muscle.
12
.submandibular gland consists of both serous and  
mucous acinar cells, which produce thicker and more viscous saliva. The main salivary duct of 
the submandibular duct is the whartons duct which passes through sublingual space and enters 
the oral cavity near the lingual frenula. Submandibular gland mainly secrets saliva in non –
stimulated conditions and contributes up to 90% of total salivary output at the resting state. It 
secrets 20-40% of total saliva in stimulated conditions.
13 
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Sublingual gland: 
 Sublingual gland is the smallest major salivary gland, which is located in the floor of the oral 
cavity, lateral to geniohyoid muscle, superior to mylohyoid muscle and medial to mandible 
similar to submandibular gland, sublingual gland also composed of both serous and mucous 
acinar cells, which reduce 2-5% of the total saliva upon stimulation.
12,13
 the intra glandular 
ducts of sublingual glands may either drain in to wharton’s duct or empty in to the floor of the 
oral cavity. 
RADIATION INDUCED COMPLICATIONS 
The oral complications of head and neck radiation can be divided into two groups on the basis 
of the usual time of their occurrence. 
*ACUTE COMPLICATIONS – A therapeutic dose of radiation in head and neck cancer 
usually comprises a total of 64 Gy to 70 Gy in 32–35 fractions with the daily dose of 1.8–2.0 
Gy/fraction.  
Acute complication appears 1–2 weeks after radiation starts, it depends on dose and site of 
radiation. It includes 
Oropharyngeal mucositis(8) 
Change in salivary composition 
Alteration of taste (Dysguesia) 
Infection (bacterial, fungal and viral) 
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CHRONIC COMPLICATION: 
Trismus and fibrosis 
Malnutrition 
Osteo radionecrosis  
Dental caries 
Xerostomia 
These symptoms can subside 2–4 weeks after completion of radiotherapy occasionally tissue 
necrosis can be seen late during therapy, but this is relatively rare.
14
 
EFFECT OF RADIATION ON ORAL AND SALIVARY GLAND TISSUS: 
Radiotherapy for head and neck tumours is a viable treatment modality. Radiotherapy is 
concerned with the delivery of the correct radiation dose to the tumour mass. While 
minimizing the dose received outside the tumour zone.  Rothwell states that most orofacial 
complications are dose dependent and that severe side effects occur when doses greater than 
45 Gy are administered bilaterally to the mouth, jaws and salivary glands. Radiotherapy for 
malignancies in the oropharyngeal region consist of 2 Gy delivered daily and bilaterally 
through 8 x 10 cm fields over the oropharynx for a weekly exposured to 10Gy. This is 
continued typically until a total of 50 Gy is admnistered 
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Oral Mucous Membrane 
 Oral mucosal response to irradiation, by a series of changes which are related to dose 
and duration of therapy. Fractionated doses, each of 2 Gy / day result in the development of 
mucosal erythema within one week. At doses up to 1.8 Gy five times weekly all killing are 
repopulation of mucous membrane stem cells are essentially in equilibrium. 
Daily treatment doses greater than 2Gy and large treatment volumes result in cell 
killing exceeding the proliferative capacity. As a result almost all patients develop a confluent 
mucositis by the third week. The mucosal erythema is due to thinning of epithelium and 
vascular dilation, inflammation and oedema of the submucosa. With continued radiotherapy, 
the mucosa becomes denuded, ulcerated and covered with fibrinous exudates.
15
 
Mucositis commonly persists for two – three weeks after completion of radiotherapy. 
Taste buds: 
 Taste buds are sensitive to radiation. Patients often note loss of taste acuity during the 
2
nd
 and 3
rd
 week of radiotherapy. Bitter and acid flavours are more severely affected when the 
posterior two thirds of the tongue is irradiated and salt and sweet when anterior third of tongue 
is irradiated. Alteration in saliva may account partly for this reduction, which may proceed to 
a state of virtual insensitivity, with recovery to near normal level, some 60 to 120 days after 
irradiation
15
. 
Teeth: 
 Irradiation of teeth with therapeutic doses during their development severely retards 
their growth. If it precedes calcification, irradiation may destroy the tooth bud. Irradiation after 
20 
 
calcification has begun may inhibit cellular differentiation causing malformations and 
arresting general growth. 
 Children receiving radiation therapy to the jaws may show defects in the permanent 
dentitions such as retained root development, dwarfed teeth or failure to form one or more 
teeth. In adults, dental pulp undergoes a decrease in vascularity with fibrosis and atrophy. 
Clinically, pulpal response to infection, trauma and dental procedures appears to be 
compromised.  
Radiation caries is a rampant form of dental decay that may occur in individuals who 
receive a course of radiotherapy that includes exposure to salivary glands. The carious lesions 
result from changes in the salivary glands and saliva, including reduced flow, decreased pH, 
reduced buffering capacity and increased viscosity. Irradiation of teeth by itself does not 
influence the course of radiation caries.  
Bone: 
 The primary damage to mature bone results from radiation induced damage to the 
vasculature of the periosteum and cortical bone. Radiation also acts destroying osteoblasts and 
to a lesser extent, osteoclasts. Ewing first described vascular irradiation injury in bones. He 
observed the formation of sclerotic connective tissue in the marrow cavity, obliterative 
endarteritis and periarteritis. Subsequent to radiation, normal marrow may be replaced with 
fatty marrow and fibrous connective tissue. The marrow tissue becomes hypovascular, 
hypoxic and hypocellular. When these changes are so severe, that bone death results, the 
condition is termed osteoradionecrosis.
15, 16,17 
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RADIATION EFFECTS ON SALIVARY GLANDS: 
Radiotherapy (RT) is commonly used to treat head-and-neck tumors. In these treatments, 
parotid, submandibular and minor salivary glands are often incidentally irradiated. Salivary 
gland parenchyma is very sensitive to radiation (the parotid gland is more sensitive compared 
with the submandibular gland).
21
   
        Radiotherapy alters the parenchymal structure and vascularity of salivary glands which 
result in volume and viscosity changes of secreted saliva.(2) Ionising radiation causes 
glandular tissue damage, which may result in a rapid, irreversible loss of salivary fluid 
secretion. The glandular architecture is replaced by ductal remnants and loose fibrous 
connective tissue which is moderately infiltrated with lymphocytes and plasma cells. This 
progressive glandular, atrophy, fibrosis and reduced salivary output begins slowly after initial 
exposure and intensifies thereafter.
22 
              A reduction in salivary function is a common toxicity and reduces the patient's quality 
of life(QOL). Inadequate salivary function (“xerostomia”) leads to multiple problems, 
including poor dental hygiene, a propensity to oral infections, sleep disturbances, oral pain, 
and difficulty chewing and swallowing. Stimulated salivary production is largely (60–70% of 
total) derived from the parotid glands, with the balance from other glands. Resting 
(unstimulated) salivary production is due primarily to the submandibular and sublingual 
glands and numerous small oral salivary glands.
23 
   Saliva flow reduces by 50–60% during the first week of radiotherapy and after 6 weeks of 
radiotherapy and 60 Gy radiation it reaches 0%. This complication is more common among 
patients who receive bilateral radiotherapy.
24
 According to Deasy et al Minimal gland 
function reduction occurs at <10–15 Gy mean dose. Gland function reduction 
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gradually increases at radiation doses of 20–40 Gy, with a strong reduction (usually by 
>75%) at >40 Gy.
22 
Radiation induced xerostomia: 
       Major salivary glands are situated at the lateral facial and submandibular regions where 
they are commonly included in to or close to the target volume in radiotherapy of oral cancers. 
Parotid glands are commonly irradiated with high radiation dose in conventional RT, as they 
are in close proximity to the radiation field. High radiation dose may damage salivary glands 
leading to xerostomia. Saliva is produced by acinar cells and drained to the excretory duct 
through ductal cells, and finally secreted in to the oral cavity.
25
saliva is mainly composed of 
water(99.5%) and other components(0.5%)including amylase, inorganic salts, mucin and 
bicarbonate.
26 
It is important in the normal daily life since saliva is responsible for moistening 
and softening food during ingestion, protecting oral mucosa and teeth and breaking down 
starch by its amylase. 
           Xerostomia may seriously impair the health related quality of life of long time 
survivors after head and neck RT.
27, 28, 29 
It is because xerostomia may lead to alterations in 
speech and taste, malnutrition and difficulty in mastication and deglutition (Eisbruch et 
al.(2003), chambers et al. (2004).Oral mucosal dryness can also change the oral pH level and 
predispose to mucosal ulcerations, fissures, dental caries and oral infection.
30,31 
         According to Eisbruch et al. the radiation induced xerostomia is an irreversible 
complication for the parotid gland received with a mean dose of 26 Gy or above. The study 
suggested that a mean dose of 26 Gy was a threshold dose for parotid glands. Other studies 
showed different thresholds of radiation dose for parotid gland ranging from 20Gy to 40Gy.
32 
some studies however suggested that irreversible xerostomia could occur with a mean dose of 
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over 60Gy.
33 
Currently there are various methods for the assessment of post –RT salivary 
glands and xerostomia, include histological evaluation, sialometry, magnetic resonance 
imaging, scintigraphy ,computed tomography and ultrasonography. 
 
ULTRASONOGRAPHIC EVALUATION:  
The echogenecity of a tissue primarily relates to its stiffness, the chief source of which is 
collagen, the content and arrangement of collagen with in tissue is a major factor in 
modification of the manner and extent to which a tissue attenuates the acoustic wave. The 
applications of USG in head and neck region is for examination of the thyroid gland, the 
salivary gland, the eye, examination of fetal face and sonically guided surgery.  
Ian R Wilson (1989)
34
 concluded that USG imaging of the superficial structures of the head 
and neck region plays a significant part in the investigation of virtually all non acute 
superficial swelling and mass lesions. USG have got added advantage of enabling clearer 
definition of the tissues of the head and neck, better documentation of the range of clinical 
application, assessment of the accuracy of USG in predicting subsequent histopathologic 
findings. They have recommended that USG should be a part of the diagnostic equipment used 
in oral radiology. 
       In Europe and Asia, US is widely accepted as the first imaging method for assessment of 
lymph nodes and soft-tissue diseases in the head and neck, including major salivary 
glands.
35,36,37,38
 As the head and neck region has a complex anatomic structure, a sound 
knowledge of sonographic anatomy and spatial relationships is crucial for reliable 
performance of the examination.   Also, knowledge of the sonographic features of the most 
common diseases in this area is a requisite. 
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       It is sometimes not possible to visualize examined lesions completely at US because of 
their location, penetrating to the deep lobe of the parotid gland or behind the acoustic shadow 
of the mandible. In these situations, performance of further imaging examinations—CT or MR 
imaging is warranted. Also, in cases of suspected malignant lesions, further diagnostic 
methods (ie, CT or MR imaging) should be applied to assess possible infiltration of bones or 
deep structures invisible at US (the base of the skull, parapharyngeal space) and to evaluate 
deep-lying lymph nodes.
39, 40, 41
 On the other hand, dynamic scintigraphy is still the method of 
choice in functional evaluation of the salivary glands.
42, 43
 
                              Ultrasonography is widely used in cancer imaging and screening as it is 
safe, non-invasive, inexpensive, highly available and carries no radiation hazard. Although US 
is commonly used in the assessment of salivary gland diseases neoplasms, sjogrens syndrome, 
sialadenitis and sialolithiasis, there is scant information in the literatures about the ultrasound 
evaluation post-RT changes in the salivary glands. 
                         US allow visualization of whole submandibular gland, sublingual gland and 
the superficial lobe of the parotid gland. Deep lobe of parotid cannot be assessed by US 
because it is obscured by the acoustic shadow of the mandibular ramus.
44
In ultrasonogrphy a 
normal parotid gland appears as homogenous speckle pattern structure.
45 
 Parotid gland is 
markedly or slightly hyperechoic compared to the adjacent muscle, and the echogenecity is 
determined by the amount of fatty glandular tissue deposited in the gland.
46
Normal parotid 
lymphnodes are usually observed at the pre-auricle level or at the tail of the gland, which 
demonstrated as hypoechoic oval structures with or without hyperechoic central hilus. 
                      A normal submandibular gland is ultrasonographically shown as triangular 
structures in the transverse scan plan. Similar to the parotid gland, the normal submandibular 
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gland appears as a homogenous structure and is markedly or slightly hyperechoic when 
compared to the adjacent muscle. The normal non dilated intra glandular ducts of the 
submandibular gland are rarely seen ultrasonographically.
12 
    To the best of my knowledge there is only four studies which had documented the post-RT 
changes of salivary glands ultrasonographically. ying et al used high resolution ultrasound to 
compare the sonographic appearances of normal and post-RT parotid glands. They found the 
grey scale US could be used to assess the size, echogenicity and internal architecture of the 
parotids. The post-RT parotids appeared as a heterogenous structure, and were hypo or 
isoechoic relative to adjacent muscles, with multiple hyperechoic lines or spots and 
hypoechoic areas. The heterogenous appearance of the post –RT glands might be due to the 
patches of inflammatory infiltrate appearing as multiple hypoechoic areas, whilst the presence 
of hyperechoic lines or spots might reflect fibrosis.
47
Although this study documented the 
sonographic appearances of the post-RT parotid glands, the sample size was small. Moreover 
the study focused on the assessment of the parotid glands in nasopharyngeal carcinoma 
patients treated with conventional radiotherapy. 
                 S C H Cheng  et al.2011
48
 did study on sonographic appearance of parotid glands in 
patients treated with intensity modulated radiotherapy or conventional RT for nasopharyngeal 
carcinoma and sonographic appearance of submandibular glands in patients treated with 
external beam radiotherapy for nasopharyngeal carcinoma based on study done by ying et 
al.2007. He assessed post radiotherapy changes in parotid glands and observed a 
heterogeneous appearance of parotid gland post radiotherapy. This was in contrast to 
homogenous echotexture in normal parotid glands. 
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Imanimognaddam et al. (2012)
24
 who evaluated changes in parotid and submandibular 
glands 2 weeks and 6 weeks following radiotherapy and observed significant reduction in 
dimensions of glands. On ultrasound he found glandular texture became heterogenic, 
hypoechoeic and irregular following radiation exposure. 
Dr Rithiga gindal et al.2015
49
 did a similar study, ultrasonographic evaluation of salivary 
glands before radiotherapy and after completion of radiotherapy and found the results similar 
to S C H Cheng et al.(2011) and Imanimognaddam et al (2012). 
Saliva is a complex mixture of fluids, with contributions from the major salivary glands 
(parotid submandibular and sublingual), the minor or accessory glands. The parotid, 
submandibular and sublingual are the major salivary glands which are located outside the oral 
cavity, encapsulated and with extended duct systems to discharge their secretions into the oral 
cavity.
54, 57, 63
 
Mechanism of Secretion of Saliva 
 Saliva is formed in two stages: a primary secretion occurs in the acini, then modified as 
it passes through the ducts. The primary secretion is formed actively by the movement of 
sodium and chloride ions into the lumen, creating an osmotic gradient which leads to the 
passive movement of water. Other acinar components are added here before the fluid 
enters the duct, where sodium ions are actively reabsorbed (chloride follow passively to 
maintain electrical equilibrium) and bicarbonate ions are secreted.
50, 51
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        The macromolecular components (amylase, mucous glycoproteins, etc) are formed in 
the usual way in the acinar cell endoplasmic reticulum, processed into secretory vesicles in 
the Golgi apparatus and are exported from the cell by exocytosis. 
Composition of saliva: 
Saliva is a dilute fluid, over 99% being made up of water. The concentrations of 
dissolved solids (organic and inorganic) are characterized by wide variation, both between 
individuals and within a single individual. 
Inorganic constituents of whole saliva.
50, 53 
Sodium 13 – 80 mmol/L 
Potassium 13 – 38 mmol/L 
Calcium 0.2 – 4.7 mg/dl 
Phosphorous 2- 23 mmol/L 
Chloride 10 – 56 mmol/L 
Bicarbonate 2 – 30 mmol/L 
Fluoride 0.0005 – 0.005 mmol/L 
Organic constituents of whole saliva:  
Urea 2 – 6 mmol/L 
Uric acid 0.2 mmol/L 
Amino acids 1- 2 mmol/L 
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Glucose 0.05 mmol/L 
Lactate 0.1 mmol/L 
Fatty acids 10 mg/l 
Macromolecules in whole saliva: 
1 Total protein 1.4 – 6.4 gm/dl 
2 -Amylase 103–380 U/litre 
3 Lysozyme 109 mg/l 
4 Peroxidase 3 mg/l 
5 IgA 194 mg/l 
6 IgG 14 mg/l 
7 IgM 2 mg/l 
8 Lipid 20 – 30 mg/l 
Normal flow rate of saliva 
Unstimulated flow rate: 0.1 – 0.5 ml/min. 
Stimulated: 1.1 – 3.0 ml/min. 
Ph: 6.2 – 7.6. 
Specific gravity – 1.002 – 1.008 
29 
 
PROPERTIES AND FUNCTIONS OF SALIVA
51, 52
  
Digestion: Salivary amylase has been considered to be of significance for dental health 
because of its intraoral actions. However, starch digestion in the mouth may either be 
beneficial in aiding starch clearance, or detrimental in liberating maltose for fermentation by 
oral bacteria to form acid. 
 Salivary amylase initiates the digestions of starch, but is inactivated in the stomach 
because of the low pH and proteolytic activity there. 
1) Lubrication: 
 The lubrication of the hard and soft oral surface is very important for speech, 
mastication and swallowing, and for general oral health and comfort. Saliva provides a tissue – 
coating film that is responsible for lubrications and bolus formation, a property, which is due 
to the water, and mucous glycoproteins it contains. 
2) Dilution and Clearance: 
   The effect of water content of saliva is the dilution of substance introduced into the 
mouth, and their subsequent removal by swallowing or spitting. 
3) Neutralisation and Buffering:  
 Saliva is alkaline and is an effective buffer system. These properties protect the oral 
tissues against acids from food or from plaque. The bicarbonate ion, present especially in 
stimulated salvia is responsible for this property. Besides bicarbonate, a small amount of 
buffering is provided by the phosphate ions and proteins of saliva. 
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4) Saturation:      
 Saliva is supersaturated with respect to tooth mineral. This is responsible for the 
growth of hydroxyapatite crystals during the remineralisation phase of the caries process. 
Sailva is also a source of fluoride for plaque and for uptake into carious lesions during de and 
remineralisation. 
5) Antibacterial effects. 
  The principal action of salivary IgA is to aggregate specific bacteria and prevent their 
adhesion to oral hard and soft tissues. 
Non – Specific antibacterial proteins 
 Lysozyme: An antibacterial enzyme, which attacks components of the cells wall of 
certain bacteria leading to lysis. 
 Lactoferrin: An iron binding protein, which removes free iron from saliva, depleting 
the supply of iron needed for bacterial growth. 
 Sialoperoxiase: Oxidises salivary thiocyanate ion to hypothiocyanate, a potent 
antibacterial substances. 
6) Pellicle and plaque formation: 
 Both pellicle and plaque matrix contain glycoproteins predominantly derived from 
saliva, pellicle protects the teeth against chemical and mechanical insult. 
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Radiation effects on teeth: 
 Irradiation of teeth with therapeutic doses during their development severely retards 
their growth. If it precedes calcification, irradiation may destroy the tooth bud. Irradiation after 
calcification has begun may inhibit cellular differentiation causing malformations and 
arresting general growth. 
 Children receiving radiation therapy to the jaws may show defects in the permanent 
dentitions such as retained root development, dwarfed teeth or failure to form one or more 
teeth. In adults, dental pulp undergoes a decrease in vascularity with fibrosis and atrophy. 
Clinically, pulpal response to infection, trauma and dental procedures appears to be 
compromised.
18, 19,20
  
Radiation caries is a rampant form of dental decay that may occur in individuals who 
receive a course of radiotherapy that includes exposure to salivary glands. The carious lesions 
result from changes in the salivary glands and saliva, including reduced flow, decreased pH, 
reduced buffering capacity and increased viscosity. Irradiation of teeth by itself does not 
influence the course of radiation caries.  
          Peter Moller et al, (2004)
59
 conducted a study on 54 patients with advanced squamous 
cell carcinoma who were treated with radiation alone or in combination with surgery or 
chemotherapy or both. The flow rates, pH are buffering capacity were determined before 
during, and up to 12 months after the completion of radiation. The mean whole resting flow 
rates for all patients decreased gradually during irradiation (weeks 1 through 6.5) to 45%, 
36%, 35% 33%, 32%, 30%, and 21% compared with mean pre RTH levels. The corresponding 
values for whole stimulated saliva were 39%, 29%, 25%, 22%, 21%, 18% and 14%. 
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EFFECT OF RADIATION ON PH OF SALIVA 
                   Samuel Dreizen et al in 1976
56
 monitored 30 patients who were given a course of 
cancer radiotherapy. The pH of stimulated whole saliva was collected from these patients and 
was measured by using a Corning Model 12 Research pH meter. They observed that there was 
a slight decrease in pH from a preradiation mean of 7.01 to a mean of 6.83 after 6 weeks of 
radiation. 
 T. Vuotila et al in 2002
58
 studied the whole saliva samples of 39 head and neck cancer 
patients having radiation therapy, which were collected before, during and after radiation 
therapy. They found that the salivary flow rate, buffer capacity and pH decreased, and the 
levels of lactobacilli increased significantly during the first half of the radiation therapy. They 
correlated the endogenously activated salivary MMP – 9 with low salivary pH (P = 0.013). 
              Peter Moller et al in 2004
59
 conducted a study on 54 patients with advanced 
squamous cell carcinoma who were treated with radiation alone or in combination with 
surgery or chemotherapy or both. The pH of whole stimulated saliva (WSS) and whole saliva 
resting saliva (WRS) was measured electromechanically by using an Orion pH meter 230 A 
and a Ross electrode model 81 – 35. 
             They observed that there was an initial drop in salivary pH after 1 week of irradiation.  
At the end of radiotherapy the mean pH for WSS was 7.05, lesser than the pre-radiotherapy 
value; where as pH for WRS was 6.97, which is slightly higher than its pre-radiotherapy value. 
The lowest mean pH values during the study were recorded of 3 months post-radiotherapy 
(corresponding 80.94% for WRS and 90% for WSS of the pre-radiotherapy mean pH). 
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EFFECT OF RADIATION ON SALIVARY AMYLASE AND PROTEIN 
                   Tuula A. Makkonen et al in 1986
60
 studied eleven patients treated for malignant 
conditions of the head and neck and analyzed the radiation induced changes in the flow rate 
and protein composition of stimulated whole saliva of these patients. Paraffin-stimulated 
whole saliva samples were collected once 2 to 21 days before therapy and then after 20, 40 
and 60 Gy cumulative dose of irradiation. They found that salivary amylase activities 
decreased with increasing dose of radiation, especially when expressed as the amount of 
enzyme secreted per minute. Unusually high salivary concentrations of albumin, lactoferrin, 
lysozyme, salivary peroxidose, myeloperoxidase, and total protein were observed during the 
therapy, but most values slowly returned to pretreatment levels after cessation of radiation. 
         H. Valdez et al in 1992
57 
evaluated fifty patients with radiation induced xerostomia 
and studied the effect of differential radiation on major salivary glands. Sialochemical analysis 
included total protein, lysozyme, lactoferrin, amylase, sodium, chloride and potassium. They 
investigated that the outputs per minute of protein, peroxidase, hexosamine, amylase, 
potassium, and calcium are significantly decreased during radiotherapy and up to 6 months 
after the end of treatment. The output of peroxidase potassium, calcium had returned to normal 
18 months after radiotherapy whereas total protein, hexosamine and amylase were still 
significantly decreased. 
                 Samuel Dreizen et al in 1976
56
 monitored 30 patients who had undergo 
radiotherapy for head and neck malignancies. The salivary total protein was determined by 
Kingsley procedures. The mean value for salivary protein increased 0.53 mEq/L between the 
initial and final measurements and found that it was statistically meaningful (P< 0.001). 
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                Dr Barres Pontes C et al in 2004
61
, studied the clinical aspects and biochemical 
properties in the saliva of 21 patients prior to and following radiotherapy for head and neck 
cancer and compared with the same properties in a control group of 21 subjects free of cancer. 
The total salivary protein was determined by Bradford and method. Amylase activity was 
measured by reducing sugars released from a soluble starch substrate, quantified by the 
dinitrosalicylic method. No statistically significant alteration was observed in total salivary 
protein concentration. A statistically significant alteration was observed in total salivary 
protein concentration. A statistically significant reduction (P < 0.01) of salivary amylase 
activity (856.6 ng/mg) ± 88.0 before and 567.0 ng/mg ± 120.6 after irradiation) was observed. 
     Tomasik A et al in 1994
62
 measured the serum and salivary alpha-amylase for controls 
and patients with laryngeal carcinoma, before and after localized irradiation including salivary 
glands. A significant increase in serum amylase was observed after irradiation. Alpha-amylase 
activity in saliva was decreased after irradiation but differences were not statistically 
significant due to the significant decrease of protein in saliva of irradiated group. 
   Brown LR et al in 1976
67
 monitored the salivary and serum lysozyme, immunoglobulin, 
albumin and total protein levels in thirty patients with cancer of the head and neck before, 
during and after radiotherapy and compared with those of a group of non-irradiated non cancer 
control subjects. The mean volume-based saliva lysozyme and total protein concentrations 
were significantly higher in the cancer patients before radiotherapy than in the control group. 
During radiotherapy, the mean volume-based concentration of all protein components assayed 
increased as the saliva flow rate decreased. 
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     Funegard U et al in 1994
55
 studied the parotid saliva composition before, during and up 
to 18 months after the irradiation period in 16 cancer patients treated for malignancies in the 
head and neck region. Stimulated parotid saliva was collected prior to radiotherapy and when 
possible, weekly during treatment. Samples were taken 2, 4, 6, 12, and 18 months after the end 
of radiotherapy. The concentrations of the measured variables increased already during the 
first week of radiotherapy and at the end of the treatment period the concentrations for total 
protein, salivary peroxidase, hexosamine and salivary IgA were significantly increased. The 
concentrations for total protein, salivary peroxidase and salivary IgA were still increased 6 
months after the end of irradiation. At the 18 months observation all concentrations had 
returned to normal, as evaluated in a paired t –test. 
Nagler R et al in 1997
63
 examined various sialochemical parameters in parotid and 
submandibular secreted saliva collected from irradiated rats. Various doses of radiation from 
2.5 to 14 Gy were administered to the head and neck region and the saliva was evaluated for 
its amylase activity and the concentration of sodium, potassium, and total protein. The total 
protein concentrations of P saliva showed a radiation dose-dependent reduction at 3 days and 3 
and 9 months following 15 Gy of 93%, 82%, and 73% (P < 0.01) respectively. 
Ben Arych et al in 1975 
64
 examined a group of 15 subjects and noted a marked increase in 
sodium concentration in unstimulated whole saliva despite the marked reduction in flow rate. 
They attributed the increase to the effect of irradiation on the resorptive system in the striated 
ducts of the salivary glands. 
Donia sadri et al.2011
69
 evaluated changes in the amount of saliva and its biochemicals 
(amylase, proteins, immunoglobulins and buffering capacity) in 18 patients before and after 
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radiotherapy. The study results showed  overall reduction in pH and salivary amylase and 
increase in total protein after RT. 
EFFECT OF RADIATION ON INORGANIC CONSTITUENTS (SODIUM, 
POTASSIUM, CALCIUM) OF SALIVA 
          Jay S. Cooper et al in 1994
65
 described that the salivary flow continues the decline 
throughout a typical course of radiation treatment and may become barely measurable by the 
dent of a 6 – 8 week course. The decreased salivary viscosity, decreased pH, increased 
concentration of sodium, chloride, calcium, magnesium and protein and a decreased 
concentration of bicarbonate and IgA in the saliva. 
              Ingrid H. Valdez et al in 1992
57
 evaluated fifty patients with radiation induced 
xerostomia. The compared the major salivary gland function with that of 50 non-irradiated 
controls. They showed that the sodium concentration in patient’s saliva was increased but the 
difference was not statistically significant. The chloride content was significantly elevated for 
both parotid and SM/SL saliva (P = 0.0001). There were no difference in potassium 
concentration between patients and controls. They also showed that the patient’s total protein 
concentration was not significantly different from that of controls. 
              Sameul Dreizen et al in 1976
56
 monitored the saliva and serum electrolyte 
concentration in 30 patients, who were undergoing head and neck radiation treatment. They 
measured the salivary sodium and potassium by flame photometry method, calcium and 
magnesium by atomic absorption in a Unicam SP 1900 Atomic absorption spectrophotometer. 
The chloride and total protein were determined in a Beckman/ Spinco Ultramicro Analytical 
system by the ultra microadaptation of the Schales and Schales and Kingsley procedures 
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respectively. They showed that the mean increased 39.85 mEq/L in Na+, 20.35 mEq/L in C1
-
, 
1.29 mEq/L in Ca++ between the initial and final measurements and were all statistically 
meaningful (P < 0.001). They described that the large Xerostomia – related increase in 
salivary sodium and chloride and decrease in salivary bicarbonate found in their study 
reflected the radiation damage to both acinar and duct system. 
                    Vissink A, et al in 1990
66
 monitored the changes in the composition and rate of 
secretion of rat whole, parotid and submandibular / sublingual salvia after local irradiation of 
the salivary gland region with a single dose of 10 Gy. They collected salivary samples before 
and 1- 30 days after irradiation, after stimulation with pilocarpine maximum changes in the 
latent period, the flow rate and the composition of parotid, SM/SL saliva were observed three 
days after a radiation dose of 10 Gy. Partial recovery was seen for the latent period, (Pi), 
(Ca
2+
) and concentration of amylase, whereas the flow rate and Na
+
 remained low and K
+
 
remained high.    
       Shannon and Prigmore in April 1959
67
 were collected Whole saliva samples from 
270 healthy individuals.  Sodium, potassium and chloride and volume were estimated.  A 
positive correlation was found between volume and chloride and between volume and sodium 
while potassium was found to be independent flow rate.  
      Wu et al, in 1993
68
 confirmed, there was no significant correlation when comparing 
young and aged healthy controls regarding salivary Na+ and K+ concentration in unstimulated 
saliva and stimulated saliva.  No significant difference between Na+ and K+ concentration in 
the salivary secretion of healthy controls patients with similar flow rates was observed. 
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     G Koshy et al.2011
70
 studied whole saliva physio-biochemical changes and quality 
of life in head and neck cancer patients following conventional radiotherapy in 53 head and 
neck cancer patients, and the results demonstrated a significant decline, shift to more acidic 
pH, higher salinity, falling proteins and amylase concentrations at 6 weeks of RT. 
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MATERIALS AND METHOD 
The study was conducted after getting approval from the Institutional Ethical Committee.  
 
STUDY CENTRE:  
 1. Department of Oral Medicine and Radiology,  
 Tamil Nadu Government Dental College and Hospital,  
 Chennai – 600 003 
 
2. Bernard Institute of Radiology,  
  Rajiv Gandhi Government Hospital,  
  Chennai -600003.  
 
 3.Department of Biochemistry      
 Rajiv Gandhi Government Hospital,  
 Chennai -600003 
                
CASE SELECTION:  
               The study population include total of 30 patients, either of the sex who were 
diagnosed as oral squamous cell carcinoma based on clinical and histological findings. 
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Inclusion criteria: 
 Patients  with age group of 40-70 years , both gender 
 Patients  diagnosed as oral cancer in Dept.Oralmedicine and 
Radiology.TNGDC,Chennai  and referred patients from Radiation 
oncology,RGGGH,Chennai. 
 Patients who planned for Radiotherapy. 
 Oral cancer patients who are willing to take part in the study.  
Exclusion criteria: 
 Patients not willing to participate in the study 
 presence of associated diseases such as Sjogren’ s  disease, salivary gland masses, 
human immunodeficiency virus, diabetes mellitus, liver cirrhosis or autoimmune 
diseases. 
 History of previous radiotherapy. 
 Patients under prolonged drug therapy.  
ARMAMENTARIUM REQUIRED FOR EXAMINATION (Fig.1) 
 Mouth mirror 
 Probe 
 Tweezer 
 Mask and glove 
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MATERIALS USED: 
 Ultrasonographic machine 
1. PHILIPS clear Vue 350 
2. High frequency transducer 13-5 
 Graduated sterile cup to collect unstimulated whole saliva 
 Universal pH paper with range 2-10.5 
 REMI R-8M Centrifugal machine 
 EasyLyte Na/K  analyzer 
 ERBA 640 clinical chemistry discrete Random access Auto analyzer. 
METHODOLOGY: 
               A total of 30 oral cancer patients who fulfilled the inclusion and exclusion criteria 
were selected for this study. Among the 30 patients 23 were males and 7 females. Age range 
of the patient was 30-70. All planned for conventional radiation treatment with cobalt 60 
apparatus in the department of radiation Oncology, RGGGH, Chennai for carcinoma of the 
oral cavity. Field of RT unilateral or bilateral. The treatment planned for 5 days in a week. The 
weekly dosage was 10 Gy (gray). The total dosage given varied from 60 to 66 Gy and 
administered over a period of 6 to 7 weeks. 
          Ultrasonographic evaluation of 60 parotids and 60 submandibular glands were done 
prior to radiotherapy and six weeks after completion of radiotherapy to evaluate the length, 
width, depth, echotexture, echogenicity, and vascularity of salivary glands.  
          In the ultrasound examination, patients laid supine on the examination bed, with neck 
extended, the right & left parotid glands, and right & left submandibular glands were assessed 
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separately with the patients head turned away from the side of examination. Sonographical 
evaluations were performed by an expert radiologist at Bernard Institute of Radiology,  Rajiv 
Gandhi Government Hospital  in two stages: I, prior to the radiotherapy; stage II, six weeks 
after radiotherapy. Length, width and depth were measured for each parotid and 
submandibular gland             
              To evaluate the length of the parotid gland, the probe was situated longitudinally 
behind the ramus of the mandible and the maximum value was measured.  
               To evaluate the length of submandibular gland, the probe was situated parallel to the 
inferior edge of the mandible and the maximum value was measured. The widths of parotid 
and submandibular glands were also measured by placing the probe vertically in the middle of 
the ramus of the mandible and vertically to the body of the mandible, respectively, and the 
maximum values were measured. The depth was identified as the distance between the 
retromandibular vein and the gland capsule.  
               Gland margins, echogenicity and echotexture were also evaluated. Echogenicity is 
described as hyperechoic (denoting a region in an ultrasound image in which the echoes are 
stronger than normal or than surrounding structures), isoechoic (a region in an ultrasound 
image in which the echoes are similar to the surrounding region) and hypoechoic (a region in 
an ultrasound image in which the echoes are weaker or fewer than normal or than in the 
surrounding heterogeneous. Gland margins were considered as regular or irregular. 
Vascularity assessed qualitatively by seeing the number of vessels present in a particular 
region and evaluated as normal or decreased. 
 
 
43 
 
COLLECTION OF SALIVA 
       Unstimulated  Whole saliva was collected  under resting conditions in a quiet 
room, between 8 am and noon, at least 1 hour after food intake .Patients  asked not to swallow 
and to generate saliva in their mouths and to spit into a sterile cup  for 5 minutes on the the 
same day of ultrasound, before RT and six weeks after completion of RT. After collection, pH 
was tested at once by using pH paper and the rest of the saliva was stored in deep freezer for 
further biochemical analysis. . For patients who had very sparse saliva secretion, the saliva 
collection time was extended to 15 minutes.  
Method of testing pH of saliva 
 The pH of saliva should always be tested immediately after collection, because the p 
may change due to loss of CO2 on storage. 
PROCEDURE: 
             The stimulated saliva was collected from patients as mentioned earlier. The pH 
indicator strip was placed into the sample of saliva for 10 seconds. Then the colour of the strip 
was checked and compared with the testing chart provided in the pH strip book . The range of 
pH from 2.0 to 10.5 can be checked using this saliva pH strip. 
 REMI R-8M Centrifugal machine 
Procedure: The sample was transferred to the appropriate test tube and centrifugation done at 
3000 rpm for 10 minutes. 
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ESTIMATION OF SALIVARY SODIUM AND POTASSIUM: 
Method: EasyLyte Na/K analyzer. Medica Corporation. 
Principle: Ion selective Electrode. 
 PROCEDURE: 
            The centrifuged saliva sample is alliquoted and placed in to the analyser the results 
were displayed . 
  Reference range: 
           Sodium-       2-21mmol/l 
           Potassium-   10-36mmol/l 
ESTIMATION OF SALIVARY CALCIUM, AMYLASE AND TOTAL PROTEIN: 
PROCEDURE:  
           The centrifuged sample was placed in the sample tray of ERBA 640 clinical chemistry 
discrete Random access Auto analyser for analysis and the results were displayed in the 
screen. 
METHOD OF SALIVARY CALCIUM ESTIMATION IN ERBA 640: 
PRINCIPLE 
           Arsenazo III combines with calcium ions at pH 6.5 to form a coloured chromophore, 
the absorbance of which is measured at 650 nm (650-660 nm) and is proportional to calcium 
concentration. Arsenazo III has a high affinity (k° = 1 x 10 -7) for calcium ions and shows no 
interference from other cations  normally present in serum, plasma or urine. 
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REAGENT COMPOSITION 
R1 
Arsenazo III- 0.10 mmol/l 
Phosphate buffer (pH 7.8 ± 0.1) 50 mmol/l 
R2 standard  
Measuring range: 0.6 – 16 mg/dl 
Reference range:1.2-2.8mmol/l 
METHOD OF ESTIMATION OF SALIVARY ALPHA AMYLASE IN ERBA 640 
 PRINCIPLE 
2-Chloro-4-nitrophenol-β -1- 4 galactopyranosylmaltotrioside (CNP-G) is a direct 
substrate for determination of α-amylase activity, which does not require the presence of 
ancillary enzymes. The rate of 2-chloro-4-nitrophenol formation can be monitored at (400-
420) nm and is proportional to the α-amylase activity. 
                              Gal – G2 - α-CNP----------------> Gal – G2 + CNP 
REAGENT COMPOSITION 
R1 
MES buffer 50 mmol/l 
Calcium Chloride 3.81 mmol/l 
Sodium Chloride 300 mmol/l 
Potassium Thiocyanate 450 mmol/l 
Sodium Azide 13.85 mmol/l 
CNPG 0.91 mmol/l 
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Measuring range: 10.8 – 1500 U/l 
 Reference range: 27 ± 3  - 144  ± 160 U/l 
METHOD OF ESTIMATION OF SALIVARY TOTAL PROTEIN IN ERBA 640: 
PRINCIPLE 
              Biuret method. The peptide bonds of protein react with copper II ions in alkaline 
solution to form a blue-violet ion complex, (the so called biuret reaction), each copper ion 
complexing with 5 or 6 peptide bonds. Tartrate is added as a stabilizer whilst iodide is used to 
prevent auto-reduction of the alkaline copper complex. The colour formed is proportional to 
the protein concentration and is measured at 546 nm (520-560). 
 
REAGENT COMPOSITION 
R1 
Copper II Sulphate 12 mmol/l 
Potassium Sodium Tartrate 31.9 mmol/l 
Potassium Iodide 30.1 mmol/l 
Sodium Hydroxide 0.6 mol/l 
R2 standard  
 Measuring range: 0.37 – 15 g/dl 
 Reference range:1.4-6.4g/dl 
		
1. ARMAMENTARIUM                             2.  USG MACHINE 
 
                          
 
 
 
 
 3.CENTRIFUGAL APPARATUS           4.EASYLYTE  
                  
 
		
           5. ERBA 640                                               6. ERBA KIT 
 
                         
 
 
 
 7. CALCIUM KIT                                           8. PH STRIP 
                        
 
		
9. PRE RADIOTHERAPHY            10.POST RADIOTHERAPHY 
                    
 
 
11. COBALT 60 APPARATUS              12. USG EVALUATION 
                
		
13. LENGTH, WIDTH, DEPTH, MARGIN, ECHOTEXTURE 
AND ECHOGENICITY OF RIGHT PAROTID-PRE RT 
           
 
 
 
14.   VASCULARITY –PRE RT 
       RIGHT PAROTID                                       RIGHT SUBMANDIBULAR 
              
		
15. LENGTH, WIDTH, DEPTH, MARGIN, ECHOTEXTURE, 
ECHOGENICITY OF RIGHT SUBMANDIBULAR GLAND-
PRE RT 
         
 
 
 
 
16. LENGTH, WIDTH, DEPTH, MARGIN, ECHOTEXTURE, 
ECHOGENICITY OF RIGHT PAROTID -POST RT 
           
		
17. LENGTH, WIDTH, DEPTH,MARGIN, ECHOTEXTURE,  
ECHOGENICITY OF RIGHT SUBMANDIBULAR-POST RT 
        
 
 
 
18.   VASCULARITY-POST RT 
      RIGHT PAROTID                        RIGHT SUBMANDIBULAR 
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STATISTICAL ANALYSIS:                          
  Statistical analysis was done by computer software program SPSS 18.01. 
  Paired sample t test was conducted to assess the level of significance of the differences 
in size  (length, width & depth) and Pearson chi-square test was conducted to assess the level 
of significance of the difference in margin, echo texture, echogenicity and vascularity of 
Parotid and submandibular salivary glands in oral cancer patients before and after 
radiotherapy. Paired sample t test was used to assess the level of significance of difference in 
biochemical changes of saliva before and six weeks after radiotherapy. Association of TNM 
staging with quantitative variables was done by using one way ANOVA. Pearson chi-square 
test was conducted to analyze the association of TNM staging with qualitative variables 
margins, echo texture, echogenicity, and vascularity.  
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RESULTS 
      Total 30 patients with oral carcinoma who fulfilled the inclusion and exclusion criteria 
were selected for the study.  Out of 30 patients 23 males (76.7%) and 7 females (23.3%) were 
present. The maximum age of the patient was 70, and the minimum was 30,with a mean 51.3. 
The given dose was minimum 60 Gy, maximum 66 Gy with a mean 63.6. 
              Out of 30 patients 20% patients were having carcinoma on right buccal mucosa, 6.7% 
patients were having carcinoma on left buccal mucosa, 13.3% patients on anterior 2/3 rd of 
tongue,13.3% patients on right lateral surface of the tongue, 16.7% patients were having 
carcinoma on floor of the mouth,3.3% patients were having on right side alveolus and hard 
palate, 6.7% patients were having carcinoma on right buccal mucosa and floor of the 
mouth,10% patients were having carcinoma on anterior 2/3 rd of the tongue and floor of the 
mouth,3.3% patients were having on right buccal mucosa and right alveolus,3.3% patients left 
buccal mucosa and retromolar region, and 3.3% of patients having carcinoma on left side 
alveolus, hard palate and retromolar trigone.  
A total of 60 parotid glands and 60 submandibular glands were evaluated with 
ultrasonography in 30 patients treated with conventional RT before and six weeks after 
radiotherapy. 
Pre radiotherapy (stage I) ultrasonographic evaluation of  right parotid gland  showed the 
mean length of 3.3±0.6,width 1.8±0.7,depth 1.9±0.7 .Post radiotherapy (stage II) 
ultrasoographic evaluation of  right parotid gland  showed  that the mean length ,width, and 
depth dimensions were significantly reduced to 2.5±0.6,1.2±0.3,1.3±0.4 respectively . Showed 
statistically significant P value 0.000 
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        Likewise stage I left parotid gland mean  length 3.2±0.6, width 1.5±0. depth1.7 ±0.9 
significantly reduced in to mean length 2.6 ±0.5, width 1.2 ±0.5, depth1.3 ±0.4 in stage II. 
Stage I USG evaluation of right submandibular gland  showed mean length 3 ±0.3,width 1.3 
±0.6,depth 1.7 ±0.6 which significantly reduced in stage II as 2.3 ±0.4,1 ±0.2,1.2 ±0.4 
respectively. Left submandibular gland showed mean length 2.9 ±0.3,width 1.3 ±0.3,depth1.6 
±0.8 in I stage USG evaluation. On stage II evaluation mean length 2.4 ±0.3,width  ±2.4,and 
depth1.2 ±0.4 
     We found the results were statistically significant P value0.000(P<0.005)  Results showed 
that there was a highly significant reduction the mean length, width, depth dimension of the 
right parotid gland, left parotid gland, right submandibular gland before and six weeks after 
radiotherapy. However there was statistically significant difference in the mean length, mean 
depth dimensions, of the left submandibular gland, mean width dimension showed no 
significant difference.  
               There was a significant difference present in margin, echotexture and echogenicity, 
and vascularity in both right and left parotid glands& right and left submandibular glands. In 
stage I ultrasonographic evaluation of right parotid gland showed 100% of regular margin. In 
stage II 10% of patients showed regular margins, 90% of the patients showed irregular 
margins of the gland. In stage I left parotid evaluation 100% patients showed regular margins 
which had been turned irregular (100%) in stage II. 
       Ultrasonographic evaluation of right submandibular gland revealed 100% of patients had 
regular margins in stageI. In stage II, 53.3%% patients had regular margins and 46.7% patients 
showed irregular margin of the right submandibular gland. In stage I evaluation of left 
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submandibular gland 100% patients showed regular margins of the gland, in stage II,63% 
patients showed irregular margin. We found the results were statistically significant P value 
0.000 (P<0.005). This result showed that there were significant changes in the margin after 
radiotherapy when compared to pre radiotherapy.  
           With respect to glandular texture, both the salivary glands (right & left) on 
Ultrasonography showed homogenous echotexture before radiotherapy. In stage I 100% 
patients having homogenous echotexture in right parotid and left parotid. On evaluation of 
stage II, 6.7% patients showed homogenous echotexture, 93.3% patients showed heterogenous 
echotexture in right parotid gland, and 100% patients showed heterogenous echotexture in left 
parotid gland. On evaluation of right submandibular gland 100% patients showed homogenous 
echotexture in stage I. On stage II 16.7% of patients showed homogenous echotexture, and 
83.3% patients showed heterogenous echotexture. On evaluation of left submandibular gland 
100% patients showed homogenous echotexture .On stage II 70% of patients showed 
heterogenous echotexture and 30% of patients showed homogenous echotexture. On the 
whole, on ultrasonography both the salivary glands showed homogenous echotexture before 
radiotherapy, which significantly changed to heterogenous echotexture six weeks following 
radiotherapy. We found the results were statistically significant P value 0.000 (P<0.005). 
                       All the patients (100%) showed hyperechoic echogenicity in both the glands 
before radiotherapy on ultrasound.16.7% of patients showed isoechoic echogenicity ,On 
evaluation of the glands six weeks after radiotherapy,  83.3% of people showed hypoechoic 
echogenicity in right parotid, 20%of patients showed isoechoic echogenecity and 80%of 
patients showed hypoechoic echogenicity in left parotid, 46.7% patients  showed hyperechoic 
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echogenicity, 33.3% patients showed isoechoic echogenicity, 20% patients showed 
hypoechoic echogenicity in right submandibular gland, 10% patients showed hyperechoic, 
20% patients showed isoechoic echogenicity,70% patients showed hypoechoic echogenicity in 
left submandibular gland. On overall echogenicity of the glands significantly changed from 
hyperechoic to hypoechoic before radiotherapy and six weeks after radiotherapy. We found 
the results were statistically significant P value 0.000 (P<0.005). 
 Both the parotid and submandibular glands were evaluated qualitatively by color doppler .Pre 
radiotherapy color doppler evaluation revealed 90% of patients showed normal vascularity, 
10% of patients showed decreased vascularity. On stage II, 73.3% showed normal vascularity, 
and 26.7% patients showed decreased vascularity. On evaluation of left parotid 90%patients 
showed normal vascularity, 10%patients showed decreased vascularity. In stage II, 66.7% 
patients showed normal vascularity and 33.3% showed decreased vascularity .90% patients 
showed normal and 10% patients showed decreased vascularity on pre radiotherapy evaluation 
of right submandibular gland. On post radiotherapy evaluation, 80% showed normal and 20% 
showed decreased vascularity on post radiotherapy evaluation.90%of patients showed normal 
vascularity and 73.3% patients showed normal, 26.7% showed decreased vascularity on post 
radiotherapy color Doppler evaluation. There was an insignificant difference in vascularity 
between pre and post radiotherapy salivary glands when evaluated qualitatively by color 
Doppler. 
Salivary biochemical analysis: 
               In the 30 oral cancer patients, the minimum value of salivary pH was 6 and 
maximum pH value was 7 before radiation. The pre radiation mean value of salivary pH was 
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6.5±0.5.Salivary pH was assessed in the same patients after six weeks of completion of 
radiotherapy. The minimum salivary pH observed was 5,and the maximum pH was 6,the mean 
value of salivary pH was 5.2±0.4.There was a statistically significant reduction in the pH 
before radiation and six weeks after completion of radiation. 
Estimation of salivary sodium before radiation in 30 oral cancer patients revealed a minimum 
value of10.7 mmol/l and a maximum level of 36.4 mmol/ l.  A mean of 19.5±6 mmol/ l was 
observed. 
Estimation of level of sodium in the saliva in the same 30 study subjects after six weeks of 
radiation, revealed a minimum value of 17.8 mmol/ l and a maximum value of 69.4 mmol/ l.  
A mean value of 43.7±12.1 mmol/ l was observed.  There was a significant increase in the 
salivary sodium the level b/w pre radiation and after 6 weeks of radiation (P = 0.000). 
The level of salivary potassium was assessed in 30 study subjects prior to radiation. The 
minimum level of salivary potassium of 11.2 mmol/l and maximum level of 32.2 mmol/l was 
observed.  The mean value of 18.4±5 mmol/l was noted (Table- 
Estimated of salivary potassium after 6 weeks of radiation in the same 30 study subjects 
showed a minimum value of 9.11 mmol/l and a maximum value of 31.2 mmol/l.  The mean 
value of salivary potassium of 16.9±5.1 mmol/l was observed.  There was a significant 
decrease in the level of potassium in the whole saliva between preradiation and after 6 weeks 
of radiation (P=0.000). 
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The level of salivary calcium was estimated for 30 study subjects before radiotherapy. The 
minimum value of salivary calcium of 1.8 mg/dl, a maximum value of 5.2 mg/dl and a mean 
value of 3.6±0.8 mg/dl was observed (Table- 5).  
Estimation of calcium in the whole saliva of the same 30 study subjects after 6 weeks of 
radiotherapy showed a minimum level of 2.4 mg/dl and a maximum level of 6.4 mg/dl.  The 
mean value of 4.7±1.1 mg/dl was observed.  There was a significant increase in the level of 
salivary calcium between preradiation and after 6 weeks of radiation was noted, (P=0.000) 
Estimation of salivary amylase before radiation in 30 oral cancer patients showed a minimum 
value of 116.2U/L and a maximum value was 1109U/L. the mean value observed was 
310±174.1.Estimation of salivary amylase in the same 30 patients six weeks after completion 
of Radiotherapy showed minimum value of 15.4,maximum value of 487.12 and the observed 
mean value was 46.2±102.6.There was statistically significant(P=0.000) reduction in mean 
values between pre radiotherapy and post radiotherapy salivary amylase estimation denoted 
that salivary amylase level was significantly reducing following radiotherapy in this study. 
The salivary total protein measured in this study in 30 oral cancer patients before radiotherapy 
showed the minimum value of 1.13g/dl, the maximum value 2.53g/dl and the mean value was 
1.5±0.3.The salivary total protein measured six weeks after completion of radiotherapy 
showed the minimum values of 1.34g/dl and the maximum value was 2.61g/dl. The mean 
value was 1.8±0.3.There was a statistically significant increase in the values between pre and 
post radiotherapy estimation of salivary total protein. In this study salivary protein level was 
significantly increased following radiotherapy. 
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Correlating TNM staging of tumor with pre and post radiotherapy, Ultrasonographic salivary 
gland  show changes as: 
Length, width, depth 
                  In this present study, TNM staging was grouped according to tumor size as group I, 
Group II and group III for the ease of comparison. We evaluated the correlation of TNM 
staging of the tumor with pre and post radiotherapy salivary gland changes. 
         When evaluated length of right parotid showed mean length of 3.5±0.4 in group I, 
3.0±0.6 in group II,and 3.3±0.2 in group III before radiotherapy. The P value for intergroup 
was 0.08 which was insignificant.  The mean length of right parotid after radiotherapy was 
2.7±0.5 for group I,2.3±0.7 for group II,and2.4± 0.3 in group III.P value for intergroup was 
0.23,which was insignificant. The mean length of left parotid for group I was 3.4±0., for group 
II 3.1±0.6,for group III 3.1±0.6 when evaluating with pre radiotherapy values, and the p value 
for intergroup. The mean length of left parotid after completion of radiotherapy, for group I 
4.8±6.3,for group II 2.4± 0.6,for group II I2.4±0.3 and the p value for intergroup was 0.06 
which was insignificant. While evaluating right sub mandibular gland, it showed mean length 
of3.6±0.2 for group I,3±0.3 for group II,2.9±0.4 for group III for before radiotherapy. And 
post radiotherapy showed 2.4±0.2 for group I,2.1±0.4 for group II,2.2±0.3 and the p value for 
intergroup value was 0.35 which was insignificant.    
         When evaluated length of left submandibular showed mean of 3.0±0.2 in group I, 
2.9±0.3 in group II, and 2.9±0.4 in group III before radiotherapy. The P value for intergroup 
was 0.7 which was insignificant. The mean length of left submandibular gland after 
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radiotherapy was 2.5±0.3 for group I,2.5±0.2 for group II,and2.3± 0.4 in group III.P value for 
intergroup was 0.53,which was insignificant. 
           When evaluated width of right parotid showed mean of 2.0±0.7 in group I, 1.6±0.6 in 
group II, and 1.9±0.26in group III before radiotherapy. The P value for intergroup was 0.36 
which was insignificant. The mean width of right parotid after  radiotherapy was 1.1±0.2 for 
group I, 1.1±0.3 for group II,and1.3± 0.3 in group III.P value for intergroup was 0.29,which 
was insignificant.  When evaluated width of left parotid showed mean of 1.7±0.7 in group I, 
1.4±0.8 in group II, and 1.4±0.2 in group III before radiotherapy. The P value for intergroup 
was 0.6 which was insignificant. The mean length of left parotid after radiotherapy was 
1.3±0.5 for group I, 1.1±0.4 for group II,and1.2± 0.4 in group III.P value for intergroup was 
0.23,which was insignificant.    
              While evaluating right sub mandibular gland, it showed mean length of3.6±0.2 for 
group I,3±0.3 for group II,2.9±0.4 for group III for before radiotherapy. And post radiotherapy 
it showed 2.4±0.2 for group I, 2.1±0.4 for group II, 2.2±0.3 and the p value for intergroup 
value was 0.35, which was insignificant. While evaluating left sub mandibular gland, it 
showed mean width of 1.3±0.3 for group I,1.2±0.3 for group II,1.5±0.3 for group III for before 
radiotherapy. The p value for intergroup was 0.311.And post radiotherapy it showed 1.1±0.2 
for group I,0.9±0.1 for group II,2.9±0.5 and the p value for intergroup value was 0.20 which 
was insignificant. 
         When evaluated depth of right parotid showed mean of 2.1±0.74in group I, 2.0±0.7 in 
group II, and 1.4±0.6in group III before radiotherapy. The P value for intergroup was 0.06 
which was insignificant. The mean depth of right parotid after  radiotherapy was 1.4±0.2 for 
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group I, 1.5±0.5 for group II,and1.1± 0.3 in group III.P value for intergroup was 0.11,which 
was insignificant.  When evaluated depth of left parotid showed mean of 1.8±0.5 in group I, 
1.8±0.7 in group II, and 1.3±0.4 in group III before radiotherapy. The P value for intergroup 
was 0.13 which was insignificant. The mean depth of left parotid after radiotherapy was 
1.4±0.4 for group I,1.3±0.5 for group II,and1.1± 0.2 in group III.P value for intergroup was 
0.35,which was insignificant.    
            While evaluating right sub mandibular gland, it showed mean depth of 1.7±0.4 for 
group I,1.8±0.8 for group II,1.2±0.2 for group III for before radiotherapy and the p value for 
intergroup value was 0.12 which was insignificant..On analyzing post radiotherapy values  it 
showed 1.3±0.4 for group I,1.3±0.4 for group II,1.0±0.4 and the p value for intergroup value 
was 0.35 which was insignificant. While evaluating left sub mandibular gland, it showed mean 
depth of 1.8±1 for group I,1.5±0.5 for group II,1.4±0.4 for group III for before radiotherapy. 
The p value for intergroup was 0.63.And post radiotherapy it showed 1.2±0.1for group 
I,1.0±0.2 for group II,1.1±0.4 and the p value for intergroup value was 0.27 which was 
insignificant. 
         On the whole although there was a highly significant difference present between 
preradiotherapy and post radiotherapy quantitative  values of  length, width, depth of right and 
left parotid and submandibular salivary glands there was not much difference in these 
parameters between TNM group I, group II, and group III which was divided based on tumor 
size.     All the qualitative values including margins, echo texture, echogenicity and vascularity 
showed insignificant p value denoted that there was not much difference in these parameters 
between TNM groups. 
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TABLE 1: AGE DISTRIBUTION 
SEX                                                   AGE TOTAL 
 30-40 40-50 50-60 60-70  
MALE 4 6 6 7 23 
FEMALE 1 2 0 4 7 
 
 
 
 
 
TABLE 2: SITE OF LESION AND ITS FREQUENCY 
SITE FREQUENCY VALID 
PERCENT 
Rt Buccal Mucosa 6 20.0 
Left Buccal Mucosa 2 6.7 
Ant 2/3rd of tongue 4 13.3 
Rt Lateral Surface of 
Tongue 
4 13.3 
Floor of the mouth 5 16.7 
Rt side Alveolus/ Hard 
Palate 
1 3.3 
Rt Buccal Mucosa + 
Floor of Mouth 
2 6.7 
Ant 2/3rd of tongue + 
FOM 
3 10.0 
Rt BM and RT Alveolus 1 3.3 
Lft BM AND RMT 1 3.3 
Left side alveolus and 
hard palate + RMT 
1 3.3 
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TABLE 3: TNM STAGING AND ITS FREQUENCY 
 
STAGE FREQUENCY VALID 
PERCENT 
T2 N0 M0 3 10.0 
T2 N0 M0 1 3.3 
T2 N1 M0 4 13.3 
T2 N2 M0 2 6.7 
T2 N2b M0 1 3.3 
T2N2cM0 1 3.3 
T3N1M0 6 20.0 
T3N2M0 2 6.7 
T3N3M0 2 6.7 
T4N0M0 3 10.0 
T4N1M0 2 6.7 
T4aN2bM 1 3.3 
T4bN1M0 1 3.3 
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TABLE 4: COMPARISION OF PRE & POST RT DIMENSIONS OFSALIVARY     
GLANDS 
 
Gland Dimension Stage Mean±S.D P 
value 
 
Right parotid Length I 3.3±0.6 0.000 
II 2.5±0.6 
Width I 1.8±0.7 0.000 
II 1.2±0.3 
Depth I 1.9±0.7 0.000 
II 1.3±0.4 
Left 
 Parotid 
Length I 3.2±0.6 0.000 
II 2.6±0.5 
Width I 1.5±0.7 0.000 
II 1.2±0.5 
Depth I 1.7±0.6 0.000 
II 1.3±0.4 
Right 
submandibular 
Length I 3.0±0.3 0.000 
II 2.3±0.4 
Width I 1.3±0.6 0.000 
II 1.0±0.2 
Depth I 1.7±0.6 0.000 
II 1.2±0.4 
       
Left 
submandibular            
Length I 2.9±0.3 0.000 
II 2.4±0.3 
Width I 1.3±0.3 0.788 
II 1.4±2.4 
Depth I 1.6±0.8 0.000 
II 1.2±0.2 
 
                  I - Pre radiotherapy, II – Six weeks after radiotherapy 
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TABLE 5:COMPARISION OF PRE & POST RT CHANGES IN MARGINS OF 
SALIVARY GLANDS 
 
GLAND STAGE                  MARGIN P 
VALUE REGULAR 
(n%) 
IRREGULAR 
(n%) 
RIGHT PAROTID I 
 
II 
30(100%) 
 
3(10%) 
0(.0%) 
 
27(90%) 
0.000 
LEFT 
PAROTID 
I 
 
II 
30(100%) 
 
0(.0%) 
0(.0%) 
 
30(100%) 
0.000 
RIGHT 
SUBMANDIBULA
R 
I 
 
II 
30(100%) 
 
16(53.3%) 
0(.0%) 
 
14(46.7%) 
0.000 
LEFT 
SUBMANDIBULA
R 
I 
 
II 
30(100%) 
 
19(63.3%) 
0(.0%) 
 
11(36.7%) 
0.000 
I - Pre radiotherapy, II – Six weeks after radiotherapy 
 
TABLE 6: COMPARISION OF PRE & POST RT CHANGES IN ECHOTEXTURE OF 
SALIVARY GLANDS 
 
GLAND STAGE               ECHOTEXTURE P 
VALUE 
 
HOMOGENOUS 
   (n%) 
HETEROGENOUS 
        (n%) 
RIGHT PAROTID I 
 
II 
30(100%) 
 
2(6.7%) 
0(0.0%) 
 
28(93.3%) 
0.000 
LEFT 
PAROTID 
I 
 
II 
30(100%) 
 
0(0.0%) 
0(0.0%) 
 
30(100%) 
0.000 
RIGHT 
SUBMANDIBULAR 
I 
 
II 
30(100%) 
 
5(16.7%) 
0(0.0%) 
 
25(83.3%) 
0.000 
LEFT 
SUBMANDIBULAR 
I 
 
II 
30(100%) 
 
9(30%) 
0(0.0%) 
 
70(100%) 
0.000 
I - Pre radiotherapy, II – Six weeks after radiotherapy 
61 
 
TABLE 7: COMPARISION OF PRE & POST RT CHANGES IN ECHOGENICITY OF 
SALIVARY GLANDS 
 
GLAND STAGE                     ECHOGENICITY P 
VALUE 
 
HYPER 
ECHOIC 
ISO 
ECHOIC 
HYPO 
ECHOIC 
RIGHT  
PAROTID 
I 
 
II 
30(100%) 
 
0(0.0%) 
0(0.0%) 
 
5(16.7%) 
0(0.0%) 
 
25(83.3%) 
0.000 
LEFT 
PAROTID 
I 
 
II 
30(100%) 
 
0(0.0%) 
0(0.0%) 
 
6(20%) 
0(0.0%) 
 
24(80%) 
0.000 
RIGHT 
SUB-
MANDIBULAR 
I 
 
II 
30(100%) 
 
14(46.7%) 
0(0.0%) 
 
10(33.3%) 
0(0.0%) 
 
6(20%) 
0.000 
LEFT 
SUB-
MANDIBULAR 
I 
 
II 
30(100%) 
 
3(10%) 
0(0.0%) 
 
6(20%) 
0(0.0) 
 
21(70%) 
0.000 
I - Pre radiotherapy, II – Six weeks after radiotherapy.  
 
TABLE 8: COMPARISION OF PRE & POST RT CHANGES IN VASCULARITY OF 
SALIVARY GLANDS 
GLAND STAGE                VASCULARITY P VALUE  
NORMAL DECREASED 
RIGHT  
PAROTID 
I 
 
II 
27(90%) 
 
22(73.3%) 
3(10%) 
 
8(26.7%) 
0.181 
LEFT 
PAROTID 
I 
 
II 
27(90%) 
 
20(66.7%) 
3(10%) 
 
10(33.3%) 
0.06 
RIGHT 
SUBMANDIBULAR 
I 
 
II 
27(90%) 
 
24(80%) 
3(10%) 
 
6(20%) 
0.472 
LEFT 
SUBMANDIBULAR 
I 
 
II 
27(90%) 
 
22(73.3%) 
3(10%) 
 
8(26.7%) 
0.181 
I - Pre radiotherapy, II – Six weeks after radiotherapy 
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TABLE 9: SALIVARY BIOCHEMICAL CHANGES 
   VALUES STAGE MEAN±S.D P VALUE 
pH I 
 
II 
6.5±0.5 
 
5.2±0.4 
0.000 
Sodium I 
 
II 
19.5±6 
 
43.7±12.1 
0.000 
Pottasium I 
 
II 
18.4±5 
 
16.9±5.1 
0.000 
 
 
Calcium I 
 
II 
3.6±0.8 
 
4.7±1.1 
0.000 
Salivary 
amylase 
I 
 
II 
310±174.1 
 
46.2±102.6 
0.000 
Total 
protein 
I 
 
II 
1.5±0.3 
 
1.8±0.3 
0.000 
                   I - Pre radiotherapy, II – Six weeks after radiotherapy  
 
 
TABLE 10: GROUPING OF TNM STAGES 
GROUPS GROUP I GROUP II GROUP III 
 
TNM 
STAGES 
T2 N2 M0 
 
T3N2c M0 
 
T4 N0 M0 
 
T2 N0 M0 
 
T3N1 M0 T4N1 M0 
 
T2 N0 M0 
 
T3 N2 M0 
 
T4aNb M0 
 
T2N1 M0 
 
 
T3N3 M0 
 
T4bN1 M0 
 
T2 N2 M0 
 
  
T2 N2b M0 
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TABLE 11:ASSOCIATION OF TNM STAGE WITH MARGIN OF THE GLANDS 
GLAND GROUP                  MARGIN P VALUE 
REGULAR(n%) 
 
IRREGULAR(n%) 
RIGHT PAROTID I 2(16.7%) 10(83%) 0.5 
II 1(9.1%) 10(90.9%) 
III 0(0%) 7(100%) 
LEFT 
PAROTID 
I 0 12(100%) 1 
II 0 11(100%) 
III 0 7(100%) 
RIGHT 
SUBMANDIBULAR 
I 8(66.7%) 4(33.3%) 0.338 
II 4(36.4%) 7(63.3%) 
III 4(57.1%) 3(42.9%) 
LEFT 
SUBMANDIBULAR 
I 8(66.7%) 4(33.3%) 0.947 
II 8(72.7%) 3(27.3%) 
III 3(42.9%) 4(57.1%) 
 
 
 
TABLE 12: ASSOCIATION OF TNM STAGE WITH ECHOTEXTURE OF THE 
GLANDS 
GLAND GROUP                  ECHOTEXTURE P 
VALUE HOMOGENOUS 
(n%) 
 
HETEROGENOUS 
(n%) 
RIGHT PAROTID I 1(8.3%) 11(91.7%) 0.5 
II 0(0%) 11(100%) 
III 1(14.3%) 6(85.7%) 
LEFT 
PAROTID 
I 2(16.7%) 10(83.3%) 0,31 
II 3(27.3%) 8(72.7%) 
III 0(0%) 7(100%) 
RIGHT 
SUBMANDIBULAR 
I 2(18.2%) 10(83.3%) 0.977 
II 2(36.4%) 9(81.8%) 
III 1(14.3%) 6(85.7%) 
LEFT 
SUBMANDIBULAR 
I 4(33.3%) 8(66.7%) 0.947 
II 3(27.3%) 8(72.7%) 
III 2(28.6%) 5(71.4%) 
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TABLE 13: ASSOCIATION OF TNM STAGE WITH ECHOGENICITY OF THE 
GLANDS 
GLAND GROU
P 
                        ECHOGENICITY P 
VALU
E 
HYPERECHOI
C 
ISOECHOI
C 
HYPOECHOI
C 
RIGHT PAROTID I 0 2(16.7%) 10(83.3%) 0.6 
II 0 1(9.1%) 10(90.9%) 
III 0 2(28.6%) 5(71.4%) 
LEFT 
PAROTID 
I 0 2(16.7%) 10(83.3%) 0.74 
II 0 3(27.3%) 8(72.7%) 
III 0 1(14.3%) 6(85.7%) 
RIGHT 
SUBMANDIBULA
R 
I 5(41.7%) 5(41.7%) 2(16.7%) 0.60 
II 7(63.6%) 2(18.2%) 2(18.2%) 
III 2(28.6%) 3(42.9%) 2(28.6%) 
LEFT 
SUBMANDIBULA
R 
I 1(8.3%) 2(16.7%) 9(75%) 0.62 
II 2(18.2%) 3(27.3%) 6(54.5%) 
III 0(0%) 1(14.3%) 6(85.7%) 
 
 
 
 
TABLE 14: ASSOCIATION OF TNM STAGE WITH VASCULARITY OF THE 
GLANDS 
GLAND GROUP                  VASCULARITY P VALUE 
INCREASE(n%) 
 
DECREASE(n%) 
RIGHT PAROTID I 10(83.3%) 2(16.7%) 0.09 
II 10(90.9%) 1(9.1%) 
III 2(28.6%) 5(71.4%) 
LEFT 
PAROTID 
I 6(50.0%) 6(50.0%) 0.80 
II 7(63.6%) 4(36.4%) 
III 7(100.0%) 0(0%) 
RIGHT 
SUBMANDIBULAR 
I 11(91.7%) 1(8.3%) 0.189 
II 9(81.8%) 2(18.2%) 
III 4(57.1%) 3(42.9%) 
LEFT 
SUBMANDIBULAR 
I 10(83.3%) 2(16.7%) 0.561 
II 7(63.6%) 4(36.4%) 
III 5(71.4%) 2(28.6%) 
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TABLE 15: COMPARISION OF TNM STAGING WITH PAROTID AND 
SUBMANDIBULAR GLANDS DIMENSIONS: 
GLAND PARAMETERS STAGE GROUP         
I 
GROUP 
 II 
GROUP 
 III 
P 
VALUE 
RIGHT PAROTID Length I 3.5±0.4 3±0.6 3.3±0.2 0.08 
II 2.7±0.5 2.3±0.7 2.4±0.3 0.23 
Width I 2±0.7 1.6±0.6 1.9±0.6 0.36 
II 1.1±0.2 1.1±0.3 1.3±0.3 0.29 
Depth I 2.1±0.4 2.0±0.7 1.4±0.6 0.06 
II 1.4±0.2 1.5±0.5 1.1±0.3 0.11 
LEFT 
PAROTID 
Length I 3.4±0.4 3.1±0.6 3.1±0.6 0.39 
II 4.8±6.3 2.4±0.6 2.4±0.6 0.35 
Width I 1.7±0.7 1.4±0.8 1.4±0.2 0.6 
II 1.3±0.5 1.1±0.4 1.2±0.4 0.23 
Depth I 1.8±0.5 1.8±0.7 1.3±0.4 0.13 
RIGHT 
SUBMANDIBULAR 
II 1.4±0.4 1.3±0.5 1.1±0.2 0.35 
Length I 3.6±0.2 3.0±0.3 2.9±0.4 0.70 
II 2.4±0.2 2.1±0.4 2.2±0.3 0.35 
Width I 1.3±0.3 1.3±0.3 1.4±0.5 0.69 
II 1.1±0.2 1.1±0.2 1.0±0.2 0.76 
Depth I 1.7±0.4 1.8±0.8 1.2±0.2 0.12 
II 1.3±0.4 1.3±0.4 1.0±0.4 0.35 
LEFT 
SUBMANDIBULAR 
Length I 3.0±0.2 2.9±0.3 2.9±0.4 0.7 
II 2.5±0.3 2.5±0.2 2.3±0.4 0.53 
Width I 1.3±0.3 1.2±0.3 1.5±0.3 0.311 
II 1.1±0.2 0.9±0.1 2.9±5.0 0.207 
Depth I 1.8±1.0 1.5±0.5 1.4±0.4 0.635 
II 1.2±0.1 1.0±0.2 1.1±0.4 0.270 
 
 
 
 
 
 
 
 
 
FIG 1: SEX DISTRIBUTION 
 
 
 
 
FIG: 2 GRAPHICAL REPRESENTATION OF TNM STAGING 
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FIG: 3 GRAPHICAL REPRESENTATION OF SITE & FREQUENCY 
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DISCUSSION 
                 Sonography is a safe and valuable technique for monitoring the changes in salivary 
glands caused by radiotherapy and provides important information regarding the morphologic 
changes of the glands.
24 
This study showed several changes of parotid and submandibular 
salivary glands when evaluated in two stages, before radiotherapy and six weeks after 
completion of radiotherapy. 
        During examination we observed decrease in overall size of salivary glands, following 
radiotherapy. There was decrease in length, width and depth of both the parotid and 
submandibular salivary glands. chronic inflammation which occurs in the salivary glands after 
exposure to radiation leads to acinar cell loss and acinar atrophy
71
 causes fibrous changes in 
the glands which subsequently leads to decrease the overall size of both parotid and 
submandibular glands. This study showed statistically significant results for all values. This 
changes were different in other organs changes those occur following radiotherapy. 
Radiotherapy causes inflammation, swelling and hyperthermia which leads to increase the 
organ size. In previous studies
72
 and Wada et al.2009 conducted a study on changes of salivary 
glands using MRI found similar results of our evaluation. Price et al reported significant loss 
of serous and mucous acini in the submandibular glands following radiation exposure over 50 
Gy
73
 documented a study on Hanford mini pigs and found following one month after 
irradiation causes parenchymal loss and acinar atrophy that leads to shrinkage of the 
submandibular salivary glands. Barker et al.2004 and lee et al.2008 documented radiation 
induced volume reduction of parotid gland by using CT. 
     Burke et al, Orloff et al,
74
  also reported similar results. Ying et al.
47
 reported only  a 
significant difference concerning the width of the parotid glands.  Eva et al reported that the 
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size of salivary glands changes only in acute situations, while in chronic conditions the size 
decreases due to the atrophy. Also stated that the reduction in size of the gland may be a end 
result of acinar atrophy and parenchymal damage.  Grehn et al.
75
 stated that the loss of acinar 
cells was dose dependent, higher radiation dose causes greater cell loss leading to loss of 
volume of the glands. S C H Cheng et al.
48
, assessed post radiotherapy changes in parotid 
glands and observed dimension changes in parotid and submandibular glands. Our study 
results were similar to Imanimognaddam et al.
24
 who evaluated changes in parotid and 
submandibular glands 2 weeks and 6 weeks following radiotherapy and observed significant 
reduction in dimensions of glands. Dr Rithiga gindal et al.
49
 did a similar study, 
ultrasonographic evaluation of salivary glands before radiotherapy and after completion of 
radiotherapy and we found the results similar to ours. 
           In this study we qualitatively evaluated margin, echotexture, ecogenicity,and 
vascularity of both right and left parotid & submandibular glands before radiotherapy and six 
weeks after completion of radiotherapy. We observed a change in margin, from regular, to 
irregular, echotexture from homogenous to heterogenous, echogenicity from hyperechoic to 
isoechoic or hypoechoic six weeks after radiotherapy. 
           The ultrasound evaluation of salivary glands of 30 oral cancer patients revealed regular 
margins before radiotherapy, 90% patients showed irregular margin on evaluation of right 
parotid, 100% patients showed irregular margin on evaluation of left parotid, 46.7% patients 
showed irregular margins on evaluation of right submandibular gland, 36.7% patients showed 
irregular margin on evaluation of left submandibular gland six weeks after completion of 
radiotherapy. The result showed statistically significant change of margins from regular to 
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irregular may be due to parenchymal loss or acinar atrophy. These results were similar to the 
previous studies conducted by   Imanimognaddam et al
24
, Dr Rithiga gindal et al
49
. 
 
           Like in the previous studies echogenicity of parotid glands were compared with 
adjacent masseter muscle. Ying et al.
47
 stated that the radiation tolerance of muscle was found 
significantly higher that of parotid gland and hence the echogenicity variation of muscle after 
irradiation should not be as much as that in parotid glands. In our study 16.7% patients showed 
isoechoic and 83.3% patients showed hypoechoic right parotid ,20% patients showed 
isoechoic and 80% patients showed hypoechoic left parotid,33.3% patients showed isoechoic, 
and 20% of patients showed hypoechoic right submandibular.20% patients showed isoechoic, 
70% hypoechoic and 10% showed hyperechoic echogenicity in left submandibular salivary 
glands. On the whole salivary glands echogenicity significantly changed from hyperechoic to 
hypoechoic after radiotherapy may be due to inflammatory infiltration and fibrosis of the 
glands. These inflammatory infiltrate could lower the echogenicity in post radiotherapy 
glands.Radfar and sirosis.
73 
            Seifert et al.
77
;Teymoortash et al.2005 stated that radiation induced chronic sialadenitis 
had been reported in the salivary glands of post RT head and neck cancer patients  
characterized by inflammatory infiltration and fibrosis histopathologically. 
               In his study ying et al.2007
47
 found that the hypoechoic inflammatory infiltrate could 
lower the echogenicity of the parotid glands, leading to decreased echogenicity in post-RT 
glands. Price et al.1995
77
 stated that the decreased echogenicity in post radiotherapy parotid 
gland was probably due to reduced refractive interfaces for ultrasound beam because of the 
loss of secretory granules and acinar cells after irradiation. S C H Cheng et al
48
, assessed post 
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radiotherapy changes in parotid and submandibular glands and observed echogenicity changed 
from hyperechoic to isoechoic and hypoechoic on ultasonographic evaluation .Our study 
results were similar to Imanimognaddam et al (2012)
24
 who evaluated changes in parotid and 
submandibular glands two weeks and six weeks following radiotherapy and observed 
significant reduction in dimensions of glands. On ultrasound he found glandular texture 
became heterogenic, hypoechoeic and irregular following radiation exposure.  
        In our study on ultrasound evaluation 100% patients showed homogenous echotexture of 
both parotid and submandibular salivary glands before radiotherapy.93.3% patients showed 
heterogenous on evaluation of right parotid, 100%  patients showed heterogenous  echotexture 
on evaluation of left parotid,83.3% patients showed heterogenous echotexture on evaluation of 
right submandibular gland, and 100% patients showed heterogenous echotexture on evaluation 
of left submandibular gland six weeks after radiotherapy..This change is due to parenchymal 
loss and acinar atrophy in irradiated glands leading to non uniform ultrasound interfaces. 
         Grehn et l.(1997),
75
and ying et al.(2007)
47
 reported that on ultrasound evaluation of 
parotid  and submandibular salivary gland showed homogenous echotexture before 
radiotherapy, where as salivary glands in the patients treated with conventional RT were 
predominately heterogenous. The heterogenous echo pattern of the parotid gland was due to 
the presence of non uniform ultrasound interfaces from the disorganized acinar cell 
arrangement after parenchymal loss and acinar atrophy in high dose irradiated glands. They 
also stated that the presence of patches of inflammatory infiltrates due to radiation induced 
chronic sialadenitis would appear multiple hypoechoic areas within the gland, leading to 
heterogenous echopattern. Our study results were similar to the previous studies conducted by 
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yang et al.(2007)
47
 , S C H Cheng et al.( 2011)
48
,  Imanimognaddam et al (2012)
24
, Dr Rithiga 
gindal et al (2015)
49
. 
                 On color Doppler we observed decrease in vascularity qualitatively six weeks after 
radiotheraphy but not considered as statistically significant. The overall decrease is because of 
destruction of glandular parenchyma secondary to radiation exposure there will be decrease 
resistance to blood flow initially but later because of both acinar, parenchymal destruction and 
endarteritis there will be decrease in blood flow in glandular tissue. In previous studies, S C H 
Cheng et al. (2011)
48
,  Imanimognaddam et al (2012)
24
, Dr Rithiga gindal et al (2015)
49
, 
authors did quantitative assessment of blood flow and velocity.  We couldn’t find any 
published data regarding the qualitative assessment of vascularity of the glands. 
                 In this study various TNM stages were grouped in to three groups based on the size 
of the tumor (T2-Group I, T3-Group II, T4-Group III) and compared with ultrasonographically 
evaluated post radiotherapy salivary gland changes. We found that the changes in the 
quantitative parameters of the salivary glands of both the parotid and submandibular salivary 
glands in between the groups were insignificant. In addition to quantitative parameters, 
qualitative parameters including margin, echotexture, echogenicity, vascularity were also 
compared, and we found that there was no statistically difference present in intergroup 
comparison. Results showed no significant difference between the groups which denotes that 
the changes in the salivary glands evaluated by ultrasound were due to effect of radiation  
irrespective of the tumor size. 
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Saliva changes: 
Few reports in the literature address the status of salivary pH after irradiation, 
especially that of whole saliva. The published data do indicate however, that irradiation to 
salivary gland appears to cause a slight decrease in the pH even in long term follow up studies. 
The present study has revealed that the mean pH for all patients had significantly reduced 
from mean value 6.5±0.5 to mean value 5.2±0.4 six weeks after completion of radiation. This 
pH is low enough to initiate decalcification of normal enamel. For pH This observation is 
consistent with the reports of Dreizen et al (1976)
54
. 
         In this present study salivary sodium level significantly increased, mean value 43.7±12.1 
after radiotherapy when compared to pre radiotherapy values ,mean value 19.5±6.And 
potassium level significantly reduced from pre radiotherapy mean value18.4±5 to post 
radiotheraphy mean value 16.9±5.1.The increased sodium and reduction of potassium maybe 
due to reduced flow rate of saliva & xerostomia induced and reflects the radiation damage to 
both the acinar and ductal systems. 
An increase in the concentrations of sodium, calcium, and magnesium has been 
reported, while the concentration of potassium is only slightly affected Dreizen et al.
54
 (oral 
sequelae) 
               The increase in the salivary calcium reflects the reduced fluid output of the acinar 
cells and resulting in the concentration of acinar products. The present study revealed that the 
mean level of salivary calcium in all the patients had increased after 6 weeks of radiation 
4.7±1.1, when compared to the pre radiation mean value 3.6±0.8. 
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Of the components studied, amylase originates from the salivary glands and thus 
serves as an indicator of the protein synthesis in the acinar cells. Makkonen T.A. et al in 
1986
60
 reported that in addition to the flow rate measurements amylase seems to be the best 
indicator of salivary gland function during radiotherapy. The present study revealed that there 
was a marked reduction in the mean salivary amylase level 46.2±102.6 when compared to the 
pre radiation mean value 310±174.1. 
           The mean value of the total protein for all patients increased from mean value 1.5±0.3 
to 1.8±0.3after 6 weeks during radiotherapy, when compared to the mean value before 
radiation. The increase in protein after radiotherapy reflects the radiation effect resulting 
acinar destruction.The finding of the marked reduction in the level of salivary amylase and 
increase the level of total protein was consistent with observations of Makkonen T.A et al
60
. 
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CONCLUSION:  
        A total of 30 oral cancer patients who fulfilled the inclusion and exclusion criteria were 
selected for this study. Among the 30 patients 23 were males and 7 females. Age range of the 
patient was 30-70. All planned for conventional radiation treatment with cobalt 60 apparatus 
in the department of radiation Oncology, RGGGH, Chennai for carcinoma of the oral cavity. 
Field of RT unilateral or bilateral. The treatment planned for 5 days in a week. The weekly 
dosage was 10 Gy (gray). The total dosage given varied from 60 to 66 Gy and administered 
over a period of 6 to 7 weeks. Ultrasonographic evaluation of 60 parotids and 60 
submandibular glands were done prior to radiotherapy and six weeks after completion of 
radiotherapy to evaluate the length, width, depth, echotexture, echogenicity, and vascularity of 
salivary glands and unstimulated whole saliva was collected before and after radiotherapy for 
analsis the levels of salivary pH,Na,K,Ca,amylase,and total protein. 
        We found that that length, width and depth of parotid and submandibular glands 
significantly reduce after radiotherapy.Also, margins, echotexture, echogenicity of the gland s 
Changes in to irregular, heterogenic,and hypoechoic respectively due to to the acini changes 
and presence of inflammatory processes.comparision of TNMstaging of the tumor based on 
size with post radiotherapy changes of the salivary glands also done which showed 
insignificant results. This denotes salivary gland changes were only dependent on radiation 
irrespective of the size of the tumor.  We  also concluded that salivary sodium,calcium and 
total protein level increases after radiotherapy and salivary PH K,and amylase significantly 
reduces after radiotheraphy. These changes can be due to parenchymal damage and acinar loss 
in the glands due to radiation. 
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PARTICIPATION INFORMATION SHEET 
 
STUDY TITLE: “Ultrasonographic analysis of salivary glands and 
Biochemical analysis of whole saliva in pre and post radiotherapy oral cancer 
patients ”  . 
Name of the Research Instituition: 
1. TamilNadu Government Dental College & Hospital, chennai-03. 
2. Barnard Institute of Radiology, RGGGH, Chennai- 01 
3. Department of Biochemistry,RGGGH,Chennai-01 
 
1. Purpose of the study:    
  To analyse  ultrasonographic changes in parotid and submandibular 
salivary glands in oral cancer patients before and after radiotherapy  and 
biochemical changes of the saliva at the same time 
 
      Procedures : 
 
1. Patient selection. 
2. Obtaining  thorough history and informed consent. 
3. Complete Clinical Examination (intra and extra oral examination) by using 
diagnostic instrument set. 
4. Ultrasound analysis of Parotid and Submandibular salivary glands is carried 
out before and after radiotherapy in  oral cancer patients. 
5. About 5ml/ table spoon quantity of Patients saliva of same patients  
a. is collected in a sterile container before and after radiotherapy  and 
b. subjected to biochemical analysis . 
3   Risk of participation : 
 Patients are selected only by proper inclusion and exclusion criteria so ,as 
the procedure is non –invasive the  risk of participation is negligible .collection of 
saliva is safe and quicker , thus sample collection is harmless to the patient. 
4.      Benefits : 
   Patients will be benefited by early diagnosis of saliva and salivary gland 
changes  by  a non- invasive  procedure.  
5.   Confidentiality : 
 The identity of the patients participating in the research will be kept 
confidential throughout the study. In the event of any publication or presentation 
resulting from the research, no personally identifiable information will be shared. 
6.   Participant’s rights: 
a).Taking part in the study is voluntary. You are free to decide whether to 
participate in the study or to withdraw at any time; your decision will not result in 
any loss of benefits to which you are otherwise entitled. 
b).The results of the special study may be intimated to you at the end of the study 
period or during the study if anything is found abnormal which may aid in the 
management or treatment. 
1. Outcome of the study: This study helps to observe salivary gland &saliva 
changes before and after radiotherapy and further helps the timely management 
of xerostomia related oral disorders in patients who are participating. 
7 .Compensation: Nil 
   8.   Contacts for queries related to the study: 
 
 
 
 
 Primary Investigator name:  Dr.R.Vasudevi. 
Contact details              :Department of Oral Medicine ad Radiology, 
                Tamil Nadu government Dental college and Hospital, 
                 Frazer Bridge Road 
                 Chennai-600003 
Phone number                   : 9677704650 
(For queries related to the rights as a study participant, please write to: The 
Chairperson, IEC-TamilNadu government dental college and Hospital,Chennai-
600003) 
	
	
	
	
	
	
	
	
	
	

Annexure: AF 06/004/01.0  
Template for Informed Consent Form  
Informed Consent Form “ULTRASONOGRAPHIC ANALYSIS OF SALIVARY 
GLANDS AND BIOCHEMICAL ANALYSIS OF WHOLE SALIVA IN PRE AND 
POST RADIOTHERAPY ORAL CANCER PATIENTS ”  
Participant ID No:  
“I have read the foregoing information, or it has been read to me. I have had the 
opportunity to ask questions about it and any questions I have asked have been answered 
to my satisfaction. I consent voluntarily to participate as a participant in this study and 
understand that I have the right to withdraw from the study at any time without in any 
way it affecting my further medical care.”  
Date Name of the participant Signature/thumb impression of the participant  
[The literate witness selected by the participant must sign the informed consent form. 
The witness should not have any relationship with the research team; If the participant 
doesn’t want to disclose his / her participation details to others, in view of respecting 
the wishes of the participant, he / she can be allowed to waive from the witness 
procedure (This is applicable to literate participant ONLY). This should be documented 
by the study staff by getting signature from the prospective participant]  
________________________________________________________________________
_____________________________________________________________________ 
 
“I have witnessed the accurate reading of the consent form to the potential participant and 
the individual has had opportunity to ask questions. I confirm that the individual has 
given consent freely”  
________________________________________________________________________ 
Date                              Name of the witness                                  Signature of the witness  
_______________________________________________________________________ 
Date                              Name of the interviewer                      Signature of the interviewer  

 DEPARTMENT OF ORAL MEDICINE AND RADIOLOGY     
TAMIL NADU GOVT. DENTAL COLLEGE & HOSPITAL, CHENNAI -3   
CASE PROFORMA 
Ultrasonographic analysis of salivary glands and Biochemical analysis of whole saliva in 
pre and post radiotherapy oralcancer patients.       
Date:                                                                            Serial no: 
Name:                                                                          O.P No: 
Age/Sex: 
Permanent address  
 
 
Temporary Address 
 
Phone no: 
Occupation:                                                                Income: 
Religion: 
District : 
State   : 
Pathology report 
Center : 
Centre:      Department of Oral Medicine And Radiology, 
      Tamil Nadu Govt Dental College & Hospital, Chennai -3 
Ref. No &Date: 
Nature of Biopsy: 
 
 
 
CASE HISTORY 
 
Presenting complaint with duration: 
 
 
History of present illness and treatment,if any: 
 
Previous illness and treatment: 
 
 
Personal history and habits 
• Frequency              : 
 
A) Smoking habit: 
• Material used: 
• Frequency      : 
• Duration of the habit: 
 
B) Chewing habit: 
• Material used: 
• Frequency      : 
• Duration of the habit: 
 
C) Other habits (alcohol, snuff): 
 
Family history: 
 
CLINICAL EXAMINATION 
Extraoral Examination: 
 
 
Intraoral examination: 
• Teeth:  
• Gingiva: 
• Labial and buccal mucosa: 
 
• Hard palate: 
 
• Soft Palate: 
 
• Pillar of fauces and Tonsils: 
 
• Tongue: 
 
• Floor of the mouth: 
 
• Retromolartrigone: 
 
 
Description of the primary lesion: 
 
 
Description of the secondary nodes: 
  Distant metastasis: 
  TNM staging: 
 Provisional diagnosis: 
       Investigations: 
 
1. Laboratory investigations: 
A. Blood: 
RBC Count: 
WBC count:  
Total count: Erythrocyte sedimentation rate: 
Differential count:                                     
 Bleeding time: 
Haemoglobin %:                                             
 Clotting time: 
Peripheral smear: 
B.  Urine: 
     Glucose: 
c) Saliva Biochemical Readings: 
S.NO  Pre radiotherapy Post radiotheraphy 
 1 Na   
2 K   
3 Ca   
4 PH   
5 Salivary amylase   
6 Salivary protein   
OTHERS: 
 
 
 
 
 
 
 
1) ULTRASONOGRAPHIC EVALUATION OF SALIVARY GLANDS  : 
 
PRE RADIOTHERAPHY 
Study parameters                            Parotid                              Submandibular 
Size(legth,width,depth)     
Ecogenicity     
Ecotexture     
Margins     
Vascularity     
 
POST RADIOTHERAPHY 
Study parameters                             Parotid                                  Submandibular 
Size(length,width,depth)     
Ecogenicity     
Ecotexture     
Margins     
Vascularity     
Clinical diagnosis: 
Treatment plan: 
 
TRIPARTITE AGREEMENT 
This agreement herein after the “Agreement” is entered into on this day --------
---------between the Tamil Nadu Government Dental College and Hospital represented 
by its Principal having address at Tamil Nadu Government Dental College and 
Hospital, Chennai – 600 003, (hereafter referred to as, ‘the college’) 
And 
Prof Dr.S.JAYACHANDRAN,M.D.S.,Ph.D., aged 52 years working as Professor 
in Department of Oral Medicine and Radiology at the Tamil Nadu Government 
Dental College, having residence address at A.M-16,TNHB quarters ,tod hunter 
nagar,Saidapet, Chennai -600015 (Herein after referred to as ‘Principal Investigator’) 
And Dr.R.VASUDEVI aged 36 years currently studying as Post Graduate student 
in Department of Oral Medicine and Radiology, Tamil Nadu Government Dental 
College, residing at No.23,A2,second floor, Swami reddy street,Egmore.Chennai-
600008 (herein after referred to as the ‘PG and co- Investigator’). 
 
Whereas the PG student as part of her curriculum undertakes this research on 
“ULTRASONOGRAPHIC ANALYSIS OF SALIVARY GLANDS AND 
BIOCHEMICAL ANALYSIS OF WHOLE SALIVA IN PRE AND POST 
RADIOTHERAPHY ORAL CANCER PATIENTS” for which purpose the Guide 
shall act as Principal investigator and the college shall provide the requisite 
infrastructure based on availability and also provide facility to the PG student as to the 
extent possible as a Co- investigator.  
Whereas the parties, by this agreement have mutually agreed to the various issues 
including in particular the copyright and confidentiality issues that arise in this regard. 
Now this agreement witnessed as follows 
1. The parties agree that all the Research material and ownership therein shall 
become the vested right of the college, including in particular all the 
copyright in the literature including the study, research and all other 
related papers. 
2. To the extent that the college has the legal right to do go, shall grant to 
licence or assign the copyright so vested with it for medical and/or 
commercial usage of interested persons/ entities subject to a reasonable 
terms/ conditions including royalty as deemed by the college. 
3. The royalty so received by the college shall be shared equally by all the 
three parties. 
4. The Co-investigator and Principal Investigator shall under no 
circumstances deal with the copyright, Confidential information and know 
– how – generated during the course of research/study in any manner 
whatsoever, while shall sole west with the college. 
5. The Co-investigator and Principal Investigator undertake not to divulge 
(or) cause to be divulged any of the Confidential information or, know – 
how to anyone in any manner whatsoever and for any purpose without the 
express written consent of the college. 
6. All expenses pertaining to the research shall be decided upon by the 
Principal investigator/ Co-investigator or borne sole by the PG student 
(Co-investigator) 
7. The college shall provide all infrastructure and access facilities within and 
in other institutes to the extent possible. This includes patient interactions, 
introductory letters, recommendation letters and such other acts requires in 
this regard. 
8. The Principal Investigator shall suitably guide Co-investigator the Student 
Right from selection of the Research Topic and Area till its completion. 
However the selection and conduct of research, topic and area of research 
by the student researcher under guidance from the Co-Investigator shall be 
subject to the prior approval, recommendations and comments of the 
Ethical Committee of the College constituted for the purpose. 
9. It is agreed that as regards other aspects not covered under this agreement, 
but which pertain to the research undertaken by the Co-investigator, under 
the guidance from the Principal Investigator, the decision of the college 
may be binding and final. 
10. If any dispute arises as to the matters related or connected to this 
agreement herein, it shall be referred to arbitration in accordance with the 
provisions of the Arbitration and Conciliation Act, 1996. 
                In witness whereof the parties hereinabove mentioned have on this day 
month and year herein above mentioned set their hands to this agreement in the 
presence of the following two witnesses. 
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